Inhibitory CCK+ basket synapse defects in mouse models of dystroglycanopathy

  1. Jennifer N Jahncke
  2. Daniel S Miller
  3. Milana Krush
  4. Eric Schnell
  5. Kevin M Wright  Is a corresponding author
  1. Neuroscience Graduate Program, Oregon Health & Science University, United States
  2. Operative Care Division, Portland VA Health Care System, United States
  3. Anesthesiology and Perioperative Medicine, Oregon Health & Science University, United States
  4. Vollum Institute, Oregon Health & Science University, United States

Abstract

Dystroglycan (Dag1) is a transmembrane glycoprotein that links the extracellular matrix to the actin cytoskeleton. Mutations in Dag1 or the genes required for its glycosylation result in dystroglycanopathy, a type of congenital muscular dystrophy characterized by a wide range of phenotypes including muscle weakness, brain defects, and cognitive impairment. We investigated interneuron (IN) development, synaptic function, and associated seizure susceptibility in multiple mouse models that reflect the wide phenotypic range of dystroglycanopathy neuropathology. Mice that model severe dystroglycanopathy due to forebrain deletion of Dag1 or Pomt2, which is required for Dystroglycan glycosylation, show significant impairment of CCK+/CB1R+ IN development. CCK+/CB1R+ IN axons failed to properly target the somatodendritic compartment of pyramidal neurons in the hippocampus, resulting in synaptic defects and increased seizure susceptibility. Mice lacking the intracellular domain of Dystroglycan have milder defects in CCK+/CB1R+ IN axon targeting, but exhibit dramatic changes in inhibitory synaptic function, indicating a critical postsynaptic role of this domain. In contrast, CCK+/CB1R+ IN synaptic function and seizure susceptibility was normal in mice that model mild dystroglycanopathy due to partially reduced Dystroglycan glycosylation. Collectively, these data show that inhibitory synaptic defects and elevated seizure susceptibility are hallmarks of severe dystroglycanopathy, and show that Dystroglycan plays an important role in organizing functional inhibitory synapse assembly.

eLife assessment

These important findings will be of interest for the study of dystroglycanopathies and in the general area of axon migration and synapse formation. This work provides convincing conclusions about how a range of dystroglycan mutations alter CCK interneuron axonal targeting and synaptic connectivity in the forebrain, and seizure susceptibility.

https://doi.org/10.7554/eLife.87965.3.sa0

Introduction

The formation of neural circuits is a multistep process involving proliferation, migration, axon guidance, maturation of neuronal subtypes, and establishment of functional synaptic connections between neurons. The cell adhesion molecule Dystroglycan is widely expressed in muscle and brain. Within the forebrain, Dystroglycan is expressed in neuroepithelial cells, pyramidal neurons, astrocytes, oligodendrocytes, and vascular endothelial cells where it plays important roles in the formation of basement membranes during early brain development (Colognato et al., 2007; Nguyen et al., 2013; Nickolls and Bönnemann, 2018; Tian et al., 1996; Zaccaria et al., 2001). At later developmental stages, Dystroglycan is present at multiple synapses, including at photoreceptor ribbon synapses in the retina (Omori et al., 2012; Orlandi et al., 2018), inhibitory synapses in the cerebellum (Briatore et al., 2010; Briatore et al., 2020; Patrizi et al., 2008), and inhibitory synapses onto pyramidal neurons (Brünig et al., 2002; Lévi et al., 2002).

Dystroglycan is a central component of the dystrophin-glycoprotein complex (DGC) known primarily for its role in the etiology of neuromuscular diseases including Duchenne muscular dystrophy (DMD), limb-girdle muscular dystrophy (LGMD), and congenital muscular dystrophy (CMD). The gene encoding Dystroglycan (Dag1) yields two subunits, the extracellular alpha Dystroglycan (α-Dag1) and the transmembrane beta Dystroglycan (β-Dag1). These two subunits are non-covalently bound, allowing Dystroglycan to function as a link between extracellular ligands and cytoskeletal and signaling proteins (Ervasti and Campbell, 1991; Holt et al., 2000; Ibraghimov-Beskrovnaya et al., 1992; Moore and Winder, 2010). Extracellular α-Dag1 interacts with multiple proteins in the nervous system through its extensive glycan chains (Jahncke and Wright, 2023). Mutations in any of the 19 genes involved in α-Dag1 glycosylation impair Dystroglycan function through reduced ligand binding and leads to a class of congenital muscular dystrophy termed dystroglycanopathy (Blaeser et al., 2013). Patients with severe forms of dystroglycanopathy frequently present with structural brain abnormalities and experience seizures and cognitive impairments (Barresi and Campbell, 2006; Muntoni et al., 2011; Taniguchi-Ikeda et al., 2016). Dystroglycanopathy patients with moderate severity can exhibit cognitive impairments even in the absence of identifiable brain malformations, suggesting that Dystroglycan functions at later stages of neural circuit formation such as synapse formation and/or maintenance (Clement et al., 2008; Godfrey et al., 2007).

The dramatic structural and anatomical phenotypes of global Dag1 deletion in mice has often precluded analysis of Dystroglycan’s synaptic functions (Myshrall et al., 2012; Satz et al., 2008; Satz et al., 2010). Recent studies show that when Dag1 is selectively deleted from postmitotic pyramidal neurons, neuronal migration and lamination is normal, however CCK+/CB1R+ interneurons (INs) fail to populate the forebrain or form synapses in these mice (Früh et al., 2016; Miller and Wright, 2021). Furthermore, conditional deletion of Dag1 from cerebellar Purkinje neurons leads to impaired inhibitory synaptic transmission and a reduction in the number of inhibitory synapses in cerebellar cortex (Briatore et al., 2020). These studies establish a role for Dystroglycan function at a subset of inhibitory synapses in the brain, but the critical features of Dystroglycan necessary for these functions, and the relationship between inhibitory synaptogenesis and neurological phenotypes in dystroglycanopathy, remains undefined.

Here, we use multiple mouse models that recapitulate the full range of dystroglycanopathy neuropathology to address several outstanding questions related to the role of Dystroglycan at inhibitory synapses. We find that CCK+/CB1R+ IN axon targeting, synapse formation, and synapse function requires both glycosylation of α-Dag1 and interactions through the intracellular domain of β-Dag1, and that defects in synaptic structure and function is associated with increased seizure susceptibility in mouse models of dystroglycanopathy.

Results

Characterizing dystroglycan localization and glycosylation in multiple models of dystroglycanopathy

While conditional deletion of Dag1 from pyramidal neurons causes a loss of CCK+/CB1R+ IN innervation in the forebrain, this has not been examined in dystroglycanopathy relevant mouse models exhibiting more widespread loss of functional Dystroglycan. We therefore generated five distinct mouse models; three to provide mechanistic insight into Dystroglycan function and two of which model mild dystroglycanopathy (schematized in Figure 1A). Since complete loss of Dag1 results in early embryonic lethality in mice, we generated forebrain-specific conditional knockouts by crossing Emx1Cre with Dystroglycan floxed mice (Dag1Flox/Flox), to drive recombination in neuroepithelial cells in the dorsal forebrain beginning at embryonic day 10.5 (E10.5) (Gorski et al., 2002; Liang et al., 2012). We verified the recombination pattern of Emx1Cre with the mCherry reporter Rosa26Lox-STOP-Lox-H2B:mCherry. H2B:mCherry signal was present in all excitatory neurons and astrocytes throughout the forebrain (Figure 1—figure supplement 1A, B and D) but not microglia or interneurons (Figure 1—figure supplement 1C and E).

Figure 1 with 2 supplements see all
Dystroglycan synaptic localization and glycosylation in mouse models of dystroglycanopathy.

(A) Schematic depiction of Dystroglycan in different mouse models. The IIH6 antibody recognizes the matriglycan repeats on extracellular αDag1. Hippocampal CA1 of P30 mice immunostained for Dystroglycan glycosylation (IIH6, green) and nuclear marker Hoechst (blue) show puncta of glycosylated Dystroglycan localized to the perisomatic region of pyramidal cells and to blood vessels (magenta arrowheads); scale bar = 50 μm. Lower panels show cell bodies in SP; scale bar = 25 μm. CA1 layers: SO, stratum oriens; SP, stratum pyramidale; SR, stratum radiatum. (B) WGA-enriched lysates from P0 forebrain were immunoblotted for IIH6, β-Dag1, and β-tubulin. (C–D) Quantification of immunoblot in (B). Error bars show mean + SEM. See Supplementary file 1 for Ns.

To model loss of Dystroglycan glycosylation, Emx1Cre was crossed with Pomt2Flox/Flox conditional mice to generate Emx1Cre:Pomt2 cKO mice. Pomt2 (protein O-mannosyltransferase 2) is a glycosyltransferase that functions in a heterocomplex with Pomt1 to add O-mannose at the beginning of the Dystroglycan glycan chain (Manya et al., 2004). Without the initial O-mannose, no additional sugar moieties can be added to the glycan chain, resulting in near complete loss of Dystroglycan glycosylation. This is lethal embryonically in a global Pomt2 knockout, however Emx1Cre:Pomt2 cKO mice are viable and survive into adulthood (Hu et al., 2016; van Reeuwijk, 2005; Yanagisawa et al., 2007).

In addition to binding extracellular ligands, Dystroglycan binds cytoskeletal proteins and signals through the intracellular tail of its β-subunit. To determine whether the intracellular domain of Dystroglycan is required for synaptic development and/or function, we examined mice in which one copy of Dag1 was deleted, and the other copy lacks the intracellular domain of β-Dag1 (Dag1cyto/-). These mice develop muscular dystrophy but show normal neuronal migration and axon guidance in regions throughout the central nervous system where Dystroglycan glycosylation is required (Lindenmaier et al., 2019; Satz et al., 2009; Satz et al., 2010).

To model mild forms of dystroglycanopathy, we examined mice expressing missense mutations in B4gat1 (β–1,4-glucuronyltransferase, B4gat1M155T) and Fkrp (fukutin related protein, FkrpP448L), two genes required for Dystroglycan glycosylation. B4gat1M155T mice were initially identified in a forward genetic screen and develop mild muscular dystrophy and have diminished ligand binding capacity due to reduced Dystroglycan glycosylation (Wright et al., 2012). The FkrpP448L missense mutation models a mutation found in a patient with dystroglycanopathy (Brockington et al., 2001). In mice, the FkrpP448L mutation leads to reduced glycosylation and mild muscular dystrophy, but no gross brain or eye malformations (Blaeser et al., 2013). While it is possible that Pomt2, B4gat1, and Fkrp could play a role in the glycosylation of proteins other than Dystroglycan, the identity of these proteins has not been described in neurons to date and we did not observe any emergent phenotypes that have not been observed in Dag1 mutants (Gerin et al., 2016; Larsen et al., 2017a; Larsen et al., 2017b; Willer et al., 2014).

We first examined the pattern of Dystroglycan localization in pyramidal neurons in CA1 of hippocampus in each of the five models by immunostaining adult (P30) mice with the IIH6 antibody, which detects the terminal matriglycan repeats on the glycan chain on α-Dag1 (Sheikh et al., 2022; Yoshida-Moriguchi and Campbell, 2015). In wild-type (WT) mice, punctate IIH6 immunoreactivity was evident in the somatic and perisomatic compartment of CA1 pyramidal neurons (Figure 1A). Immunoreactivity was also present in blood vessels, where Dag1 is also expressed (Durbeej et al., 1998; Zaccaria et al., 2001). Neuronal immunoreactivity was undetectable in Emx1Cre:Dag1 cKOs and Emx1Cre:Pomt2 cKOs, whereas blood vessel expression was maintained, illustrating the specificity of the conditional deletion (Figure 1A). Punctate perisomatic IIH6 immunoreactivity was present in Dag1cyto/-, B4gat1M155T/M155T, and FkrpP448L/P448L mice (Figure 1A). To assess Dystroglycan localization in Emx1Cre:Pomt2 cKOs we used an antibody that recognizes the intracellular C-terminus of β-Dag1. Although immunoreactivity for β-Dag1 was present and elevated above Emx1Cre:Dag1 cKO or Dag1cyto/- levels, Dag1 localization did not appear punctate in Emx1Cre:Pomt2 cKOs (Figure 1—figure supplement 2A). This apparent difference implies that Dag1 glycosylation, and by extension the extracellular interactions that matriglycan mediates, is required for proper Dag1 synaptic localization.

We next prepared WGA-enriched lysate from neonatal (P0) forebrain and immunoblotted for (1) IIH6, to quantify the degree of α-Dag1 glycosylation and (2) β-Dag1, to measure total Dystroglycan protein levels (Figure 1B). Dag1 glycosylation was significantly reduced in Emx1Cre:Dag1 cKO, Emx1Cre:Pomt2 cKO, Dag1cyto/-, B4gat1M155T/M155T, and FkrpP448L/P448L mice; however, the reduction in FkrpP448L/P448L mice was less severe than the other models (Figure 1C). The reduction in glycosylation observed in the Dag1cyto/- mice is surprising given that the mutation is restricted to the intracellular domain. Dystroglycan heterozygotes (Dag1+/-) show no reduction in IIH6 levels compared to wild-types (data not shown), so the reduction in Dag1cyto/- mice can be presumed to be due to the intracellular deletion. It is possible that the intracellular domain is required for the trafficking of Dystroglycan through the endoplasmic reticulum and/or Golgi apparatus, where Dystroglycan undergoes glycosylation, however additional work is needed to verify this. As expected, β-Dag1 immunoblotting was significantly reduced in Emx1Cre:Dag1 cKOs and absent in Dag1cyto/- mice but normal in the glycosylation mutants (Figure 1D). The residual β-Dag1 in Emx1Cre:Dag1 cKO brain is likely due to Dag1 expression in unrecombined cells, such as blood vessels, as well as unrecombined tissue that remained after the forebrain dissection.

We next examined Dag1 protein levels during synaptogenesis using WGA-enriched lysate from P21-P30 hippocampus. As expected, Dag1 glycosylation assessed by IIH6 immunoblotting was severely reduced in Emx1Cre:Dag1 cKOs and Emx1Cre:Pomt2 cKOs but normal in Dag1cyto/- mice (Figure 1—figure supplement 2B–C). Immunoblotting for β-Dag1 showed a significant reduction in Emx1Cre:Dag1 cKOs and Dag1cyto/- mutants but normal levels in Emx1Cre:Pomt2 cKOs (Figure 1—figure supplement 2B, D). Although localization of Dag1 was not punctate in Emx1Cre:Pomt2 cKOs (Figure 1—figure supplement 2A), the overall level of β-Dag1 was normal by WGA-enrichment, which enriches for proteins in the plasma membrane (Figure 1—figure supplement 2B, D). It therefore remains possible that Dag1 still trafficks to the cell surface in Emx1Cre:Pomt2 cKOs but fails to contact presynaptic axons and therefore does not permit synaptogenesis.

Dystroglycan is required for cortical neuron migration in a glycosylation-dependent manner

In neocortex, Dag1 expression in radial glia is required for proper migration of neurons, with Dag1 conditional deletion from neuroepithelial cells or radial glia resulting in Type II lissencephaly (Moore et al., 2002; Pawlisz and Feng, 2011; Satz et al., 2008; Satz et al., 2010). This requires proper Dystroglycan glycosylation, but not its expression in neurons (Chan et al., 2010; Holzfeind et al., 2002; Hu et al., 2011; Wright et al., 2012). To compare cortical migration across our five models of dystroglycanopathy, we performed immunostaining for the upper layer marker Cux1 (layers II/III-IV) and the deep layer marker Tbr1 (layers III, VI) in P30 somatosensory cortex (Figure 2A–B). Emx1Cre:Dag1 cKOs and Emx1Cre:Pomt2 cKOs showed complete cortical dyslamination with 100% penetrance, whereas the cytoplasmic (Dag1cyto/-) deletion mutants appeared normal (Figure 2C–D). B4gat1M155T/M155T missense mutants showed a migration phenotype only at the cortical midline, while FkrpP448L/P448L missense mutants did not show any cortical migration phenotype (Figure 2C–D, Figure 2—figure supplement 1A). These results indicate that cortical migration depends on Dystroglycan glycosylation but does not require its cytoplasmic domain. Furthermore, taken with the data in Figure 1B–D, they illustrate that the severity of the cortical migration phenotype scales with the degree of Dystroglycan hypoglycosylation; Emx1Cre:Dag1 cKOs and Emx1Cre:Pomt2 cKOs model a severe form of dystroglycanopathy (Walker-Warburg Syndrome, Muscle-Eye-Brain disease) and B4gat1M155T/M155T and FkrpP448L/P448L mutants modeling a milder form of the disease.

Figure 2 with 2 supplements see all
Dystroglycan is required for cortical neuron migration in a glycosylation-dependent manner and independent of intracellular interactions.

Immunostaining for cortical layer markers (A) Cux1 (layers 2–4) and (B) Tbr1 (layers 3 and 6) in P30 somatosensory cortex (scale bar = 200 μm). Layer markers are shown in green. Nuclear marker Hoechst is shown in magenta. Quantification of fluorescence intensity of layer markers shown for (C) Cux1 and (D) Tbr1. Shaded regions of intensity profile illustrate ± SEM. See Supplementary file 1 for Ns. Significance: *=p < 0.05, **=p < 0.01, ***=p < 0.001, NS = p ≥ 0.05. CC, corpus callosum; A.U., arbitrary units.

To further assess the impact of our functional domain mutations, we assessed Laminin localization, the canonical interacting partner of Dystroglycan in the extracellular matrix (ECM), in adult neocortex (Ibraghimov-Beskrovnaya et al., 1992). Under WT conditions, Laminin immunoreactivity was evident at the pial surface where Laminin and Dystroglycan interact at the interface between radial glial endfeet and the cortical basement membrane (Satz et al., 2010). Laminin was also present in blood vessels, where Dystroglycan-expressing perivascular astrocytes contribute to the maintenance of water homeostasis (Menezes et al., 2014). In Emx1Cre:Dag1 cKO cortex, Laminin immunoreactivity at the pial surface was patchy and vascular Laminin showed evidence of the neuronal migration phenotype described in Figure 2, Figure 2—figure supplement 2A. Laminin immunoreactivity in Emx1Cre:Pomt2 cKO cortex similarly showed a patchy appearance, albeit less severe than Emx1Cre:Dag1 cKOs, along with the evident cortical migration phenotype (Figure 2—figure supplement 2B). Dag1cyto/- mutants, on the other hand, exhibited normal Laminin immunoreactivity both at the pial surface and with regards to vascular organization (Figure 2—figure supplement 2C).

Perisomatic CCK+/CB1R+ interneuron targeting requires dystroglycan in a non-cell autonomous manner

CCK+/CB1R+ IN innervation is largely absent from the cortex and hippocampus when Dag1 is deleted selectively from pyramidal neurons using NeuroD6Cre (NEXCre) (Früh et al., 2016; Miller and Wright, 2021). However, the development and function of CCK+/CB1R+ INs has not been examined in mouse models that more broadly lack Dag1 throughout the CNS and thus more accurately reflect the neuropathology of dystroglycanopathy. We focused our analysis on region CA1 of the hippocampus, as its overall architecture is grossly unaffected in each of our mouse models. Both Emx1Cre:Dag1 cKO and Emx1Cre:Pomt2 cKO mice exhibited a mild granule cell migration phenotype in dentate gyrus (Figure 3A, yellow arrows); however, CA1-CA3 showed normal pyramidal neuron organization.

Figure 3 with 4 supplements see all
Dag1 is required for CCK+/CB1R+ basket IN perisomatic axon targeting in stratum pyramidale of hippocampal CA1-3.

(A) Nuclear marker Hoechst (upper panels) shows hippocampal morphology. Granule cell migration is disrupted in dentate gyrus of Emx1Cre:Dag1 cKOs and Emx1Cre:Pomt2 cKOs (yellow arrows). CA1-3 gross morphology is normal in all models. CB1R immunostaining (lower panels) shows abnormal CCK+/CB1R+ basket interneuron targeting in CA1-3 to varying degrees across models (scale bar = 400 μm). (B) Higher magnification view of CB1R immunostaining in CA1 (scale bar = 50 μm). (C) Quantification of CA1 CB1R fluorescence intensity profile. Shaded regions of intensity profile illustrate ± SEM. Gray region highlights SP. See Supplementary file 1 for Ns. Significance: *=p < 0.05, **=p < 0.01, ***=p < 0.001, NS = p ≥ 0.05. A.U., arbitrary units; SO, stratum oriens; SP, stratum pyramidale; SR, stratum radiatum.

In WT control mice, CCK+/CB1R+ IN axon terminals were abundant throughout the hippocampus, with their highest innervation density in the CA1 pyramidal cell body layer (stratum pyramidale, SP) where they form characteristic basket synapses onto pyramidal neurons (Figure 3A–C, Figure 3—figure supplement 1A). In Emx1Cre:Dag1 cKO mice, CCK+/CB1R+ axons were present but failed to target the pyramidal cell layer (Figure 3A–C, Figure 3—figure supplement 1A), a surprising difference from the phenotype observed in NeuroD6Cre:Dag1 cKO mice which lack CCK+/CB1R+ IN innervation entirely (Früh et al., 2016; Miller and Wright, 2021; Figure 3—figure supplement 1C). To confirm the CCK+/CB1R+ IN innervation pattern in the context of widespread Dag1 deletion, we generated NestinCre:Dag1 cKO mice. NestinCre, similar to Emx1Cre, drives Cre recombination in forebrain progenitors, however Emx1Cre recombination begins around E10.5 and NestinCre recombination begins around E11.5 (Liang et al., 2012; Tronche et al., 1999). NestinCre:Dag1 cKOs showed the same CCK+/CB1R+ axon targeting phenotype as Emx1Cre:Dag1 cKOs (Figure 3—figure supplement 1B), further suggesting that the observed Emx1Cre:Dag1 cKO phenotype faithfully models dystroglycanopathy neuropathology.

It was previously reported that the lack of CCK+/CB1R+ IN innervation of CA1 pyramidal neurons observed in NeuroD6Cre:Dag1 cKOs was accompanied by reduced numbers of CCK+/CB1R+ INs (Miller and Wright, 2021). We therefore sought to quantify CCK+/CB1R+ IN cell density in Emx1Cre:Dag1 cKOs using both NECAB1 and NECAB2 antibodies (Miczán et al., 2021). As NECAB1 is expressed by both CCK+/CB1R+ INs and PV+ INs, we performed immunolabeling for both NECAB1 and PV and quantified the density of NECAB1+;PV- cell bodies in CA1, finding no difference between Emx1Cre:Dag1 controls and Emx1Cre:Dag1 cKOs (Figure 3—figure supplement 2A–B). To confirm this, we also quantified the density of NECAB2+ cell bodies in CA1, again finding no difference between genotypes (Figure 3—figure supplement 2C, E). Thus, the observed change in CCK+/CB1R+ IN axon targeting of CA1 pyramidal cells is not due to a reduction in cell numbers, but rather a failure to innervate the appropriate compartment.

Emx1Cre:Pomt2 cKO mice fully phenocopied the aberrant Emx1Cre:Dag1 cKO CB1R+ immunoreactivity pattern (Figure 3A–C), demonstrating that proper CCK+/CB1R+ IN basket axon targeting requires Dystroglycan glycosylation. Both the B4gat1 and Fkrp mutants showed a normal distribution of CB1R+ axon targeting to the somatodendritic compartment of CA1 neurons, but with reduced CB1R intensity in SP (Figure 3A–C). The cytoplasmic domain of Dystroglycan also plays a role in the appropriate targeting of CB1R immunoreactive axons, as the distribution of axons was perturbed in the Dag1cyto/- mutants, although with an intermediate phenotype in which the upper portion of SP appeared normal while the lower portion of SP showed loss of selective CB1R+ axon targeting (Figure 3A–C).

Due to the axonal targeting defect in the CCK+/CB1R+ IN population, we next examined the parvalbumin (PV) population of interneurons in the hippocampus, as these cells also form perisomatic basket cell synapses on to CA1 pyramidal cells. There was no significant difference in the number of PV+ INs in CA1 of Emx1Cre:Dag1 cKO mice and littermate controls (Figure 3—figure supplement 2D and F). Furthermore, the distribution of PV+ IN axons showed normal targeting to SP in all mouse models (Figure 3—figure supplement 3A–B), indicating that the axon targeting phenotype is specific to the CCK+/CB1R+ IN population. Interestingly, Emx1Cre:Dag1 cKO mice exhibited a slight increase in PV intensity in SP, perhaps indicating that there is a degree of compensation (Figure 3—figure supplement 3A–B).

Notably, CB1R expression was also abnormal in brain regions outside of the hippocampus. In somatosensory cortex, CB1R immunostaining reflected the dyslamination phenotype in both the Emx1Cre:Dag1 cKO and Emx1Cre:Pomt2 cKO mice throughout neocortex and the B4gat1M155T/M155T mice at midline, while it appeared normal in cortex of Dag1cyto/- and FkrpP448L/P448L mice (Figure 3—figure supplement 4A). CB1R staining was also reduced and disorganized in the basolateral amygdala (BLA) in Emx1Cre:Dag1 cKO and Emx1Cre:Pomt2 cKO mice (Figure 3—figure supplement 4B). Interestingly, CB1R immunostaining in the inner molecular layer (IML) of dentate gyrus appears normal in all mutants (Figure 3A). In the IML, CB1R is present in excitatory mossy cell axons targeting dentate granule cells whereas in both cortex and amygdala CB1R expression is restricted to GABAergic interneurons (Földy et al., 2006; Katona et al., 2001; Monory et al., 2015). Therefore, glycosylated Dystroglycan instructs the development of inhibitory CB1R+ interneuron populations in multiple brain regions.

Dystroglycan is required for CCK+/CB1R+ interneuron axon targeting during early postnatal development

During early postnatal development, CCK+/CB1R+ IN axons undergo a dramatic laminar rearrangement, progressing from more distal localization amongst pyramidal cell dendrites, to eventually target pyramidal neuron cell bodies in the hippocampus (Miller and Wright, 2021; Morozov et al., 2009; Morozov and Freund, 2003a; Morozov and Freund, 2003b). We examined the developmental time course of CCK+/CB1R+ IN axon targeting in our Emx1Cre:Dag1 cKO mice beginning at P5, when the axons are first readily identifiable (Berghuis et al., 2007; Eggan et al., 2010; Mulder et al., 2008; Vitalis et al., 2008). At P5 in Emx1Cre:Dag1 control mice, CCK+/CB1R+ axons were initially concentrated in the stratum radiatum (SR) of the hippocampus (Figure 4A–C). Between P10 and P30, the CCK+/CB1R+ axons underwent developmental reorganization, with reduced innervation of SR coinciding with a progressive increase in innervation of SP. In contrast, overall CCK+/CB1R+ innervation was initially reduced in the hippocampus of mutant Emx1Cre:Dag1 cKO mice at P5, and these axons failed to undergo laminar reorganization as they developed (Figure 4A–C). By P30, after IN synapse formation and targeting are largely complete in control mice, the density of CCK+/CB1R+ axons in Emx1Cre:Dag1 cKO mice was uniform across all hippocampal lamina (Figure 4A–C). Therefore, Dystroglycan plays a critical developmental role during the first two postnatal weeks, for the proper laminar distribution and perisomatic targeting of CCK+/CB1R+ IN axons in the hippocampus.

Dag1 is required for CCK+/CB1R+ IN axon targeting during early postnatal development.

(A) Immunostaining for CB1R+ axon terminals (green) in the hippocampus of Emx1Cre:Dag1 controls (left) and cKOs (right) at ages P5-P30. Nuclear marker Hoechst is shown in magenta. White arrowheads indicate migration errors in dentate granule cells Emx1Cre:Dag1 cKO mice. Scale bar = 500 μm. (B) Higher magnification images of CB1R+ axon terminals in CA1 of Emx1Cre:Dag1 controls (left) and cKOs (right) at ages P5-P30. Scale bar = 100 μm. (C) Quantification of CB1R fluorescence intensity profile in CA1. Shaded regions of intensity profile illustrate ± SEM. Gray region highlights SP. See Supplementary file 1 for Ns. Significance: *=p < 0.05, **=p < 0.01, ***=p < 0.001, NS = p ≥ 0.05. A.U., arbitrary units; SO, stratum oriens; SP, stratum pyramidale; SR, stratum radiatum.

CCK+/CB1R+ IN synapse formation requires postsynaptic glycosylated dystroglycan

Given the perturbed distribution of CCK+/CB1R+ IN axons in the hippocampus, we next wanted to determine whether the remaining CCK+/CB1R+ IN axons were capable of forming synapses in dystroglycanopathy models. Using VGAT as a marker of inhibitory presynaptic terminals, we saw no difference in total VGAT puncta density in SP in any of the mouse models, indicating that the total number of inhibitory synapses is normal (Figure 5B–D). Immunostaining for CB1R showed a significant decrease in CB1R in SP of Emx1Cre:Dag1 cKO, Emx1Cre:Pomt2 cKO, B4gat1M155T/M155T, and FkrpP448L/P448L mutants, but not Dag1cyto/- mutants (Figure 5E). This suggests that the difference in CB1R+ axon distribution described in SP of Dag1cyto/- mutants in Figure 3A–C likely reflects a change in CCK+/CB1R+ IN axon targeting but not synapse formation, whereas Emx1Cre:Dag1 cKO and all three glycosylation mutants exhibit a reduction in CCK+/CB1R+ IN axon targeting and synapse number in SP. It should be noted that the data in Figure 3A–C reflects axonal CB1R intensity across all hippocampal layers, whereas the quantification in Figure 5E reflects the density of axonal swellings within SP. These data therefore suggest that there is an overall reduction in CB1R intensity in SP of Dag1cyto/- mutants that does not influence the number of CB1R+ axonal swellings. In contrast to CCK+/CB1R+ INs, the PV+ population of basket interneurons showed no change in puncta density in SP in any of the models (Figure 5—figure supplement 2A–E; analysis of VGAT, CB1R, and PV densities in SO and SR included in Figure 5—figure supplement 1A–B and Figure 5—figure supplement 3A.)

Figure 5 with 3 supplements see all
Dag1 and Pomt2 cKOs exhibit impaired CB1R+ basket synapse formation in stratum pyramidale of hippocampal CA1.

P30 coronal sections immunostained for (A) CB1R and (B) VGAT in hippocampal CA1; merged image in (C) shows CB1R in magenta and VGAT in green. (A–C) Scale bar = 50 μm. (Higher magnification view of SP in (C’); scale bar = 10 μm.) (D) Quantification of VGAT puncta density in SP expressed as a percent of control. (E) Quantification of CB1R puncta density in SP expressed as a percent of control. (F) Quantification of co-localization between VGAT and CB1R in SP to estimate putative CB1R+ basket cell synapse formation. Error bars show mean + SEM. (For quantification of puncta densities and co-localization in SO and SR see Figure 5—figure supplement 1.) See Supplementary file 1 for Ns. Significance: *=p < 0.05, **=p < 0.01, ***=p < 0.001, NS = p ≥ 0.05. SO, stratum oriens; SP, stratum pyramidale; SR, stratum radiatum.

To better approximate the extent of basket synapse formation, we quantified the co-localization between VGAT and CB1R or PV. In SP, the percent of CB1R puncta co-localized with VGAT was reduced in the same models that showed a reduction in CB1R density (Emx1Cre:Dag1 cKO, Emx1Cre:Pomt2 cKO, B4gat1M155T/M155T, and FkrpP448L/P448L mutants) but not Dag1cyto/- mutants (Figure 5C and F), suggesting that CCK+/CB1R+ INs require postsynaptic glycosylated Dystroglycan in order to form synapses whereas the cytoplasmic domain is required for axon targeting but not synapse formation.

Interestingly, the percent of PV co-localized with VGAT increased in the SP of Emx1Cre:Dag1 cKO and Emx1Cre:Pomt2 cKO mice, with no change in any of the other models (Figure 5—figure supplement 2C, E; analysis of co-localization in SO and SR included in Figure 5—figure supplement 1C, Figure 5—figure supplement 3B). It is possible that the reduction in inhibitory CCK+/CB1R+ synapses prompts homeostatic compensation through an increase in PV+ synapses. Alternatively, this may reflect competition between CCK+/CB1R+ and PV+ INs for physical space on the perisomatic region of pyramidal cells, with the decrease in CCK+/CB1R+ synapses in Emx1Cre:Dag1 cKOs and Emx1Cre:Pomt2 cKOs allowing additional PV+ IN synapses to form.

CCK+/CB1R+ interneuron basket synapse function is dependent on dystroglycan function

Perisomatic inhibitory basket cell synapses powerfully control activity in the hippocampal circuit (Freund and Katona, 2007). Previous studies in NeuroD6Cre:Dag1 cKO mice, in which CCK+/CB1R+ INs are absent, demonstrated reduced inhibitory synaptic function (Früh et al., 2016). In the current study, however, CCK+/CB1R+ INs are present but mistargeted. Thus, we wanted to determine whether with the changes in CCK+/CB1R+ basket synapse localization in our mouse models were associated with altered inhibitory synaptic function. CCK+/CB1R+ IN basket cells can be selectively activated by muscarinic receptor activation, which increases the rate of spontaneous inhibitory post-synaptic currents (sIPSCs) in nearby pyramidal cells (Früh et al., 2016; Nagode et al., 2014). Thus, to assay function at CCK+/CB1R+ IN synapses, we performed whole cell patch clamp electrophysiology from CA1 pyramidal neurons in slices from control and mutant mice. After recording 5 minutes of baseline sIPSCs, the cholinergic receptor agonist Carbachol (CCh) was added to the bath and an additional 5 minutes of sIPSCs were recorded. While both Emx1Cre:Dag1 control and Emx1Cre:Dag1 cKO cells displayed a CCh-mediated change in sIPSC frequency, this response was dramatically attenuated in Emx1Cre:Dag1 cKOs mice compared to Emx1Cre:Dag1 control mice (Figure 6A–C). Furthermore, in Emx1Cre:Dag1 controls, 19/21 cells (90.5%) responded to CCh application (defined as a>20% increase in sIPSC frequency), whereas only 13/22 cells (59.1%) responded in Emx1Cre:Dag1 cKOs (Figure 6—figure supplement 1B). Proper Dystroglycan glycosylation was also required for CCK+/CB1R+ IN synapse function, as Emx1Cre:Pomt2 cKO mice exhibited the same phenotype as Emx1Cre:Dag1 cKOs: a reduced response to CCh overall, and a reduced proportion of responsive cells (Figure 6A–C, Figure 6—figure supplement 1B). CCh also increased the mean sIPSC amplitude in each of the controls (Figure 6—figure supplement 1A), which may reflect an increased contribution of larger-amplitude action potential-mediated perisomatic events elicited by CCh (Früh et al., 2016; Nagode et al., 2014). Consistent with the decreased function of CCK+/CB1R+ IN synapses, a CCh-mediated change in sIPSC amplitude was also absent in each of these models (Figure 6—figure supplement 1A). Together, these data indicate that the altered perisomatic CCK+/CB1R+ IN synaptic localization in CA1 is associated with a functional deficit in synaptic signaling.

Figure 6 with 1 supplement see all
Dag1 is required for CCK+/CB1R+ IN synapse function in hippocampal CA1 in a manner dependent on both glycosylation and intracellular interactions.

(A) Representative traces showing + seconds of sIPSC recordings at baseline (top) and after the addition of carbachol (bottom). (B) Quantification of average sIPSC frequency at baseline and after the addition of carbachol. (C) Quantification of the change in sIPSC frequency with the addition of carbachol. Error bars show mean + SEM. See Supplementary file 1 for Ns. Significance: *=p < 0.05, **=p < 0.01, ***=p < 0.001, NS = p ≥ 0.05. Abbreviations: sIPSC, spontaneous inhibitory postsynaptic current; CCh, carbachol.

Dag1cyto/- mutants also had a dramatically attenuated sIPSC response to CCh compared to WT controls (Figure 6C). Notably, even baseline sIPSC frequency was reduced in Dag1cyto/- mutants (2.27±1.70 Hz) compared to WT controls (4.46±2.04 Hz, p=0.002), whereas baseline sIPSC frequencies appeared normal in all other mutants when compared to their respective controls. Together with the finding that these mutants contain a normal number of CCK+/CB1R+ basket synapses (as measured using immunohistochemistry; Figure 5A–D), these results indicate that the cytoplasmic domain of Dystroglycan may play a critical role in mediating the assembly of functional postsynaptic signaling/receptor complexes at these synapses.

Neither of the more mildly hypoglycosylated mutants (B4gat1M155T/M155T, FkrpP448L/P448L) were different from their respective littermate controls in terms of the magnitude of the CCh effect on sIPSC frequency (Figure 6C), although the B4gat1WT mice appeared to possess a reduced effect of CCh compared to other control conditions (Figure 6A–C). The B4gat1 line is of a mixed genetic background, which could possibly explain the difference in CCh response. This finding is of unclear significance and may have obscured potential differences. Importantly, however, the marked functional synaptic differences observed between the Emx1Cre:Pomt2 cKO, Emx1Cre:Dag1 cKO and Dag1cyto/- mice when compared with each of their respective controls described above was not seen in either of these phenotypically milder mutants.

Together, these results suggest that Dystroglycan is required for the function of CCK+/CB1R+ IN perisomatic basket synapses in a glycosylation-dependent manner, as evidenced by the Emx1Cre:Dag1 cKO and Emx1Cre:Pomt2 cKO synaptic phenotypes, and that the intracellular domain of Dystroglycan is also required for normal CCK+/CB1R+ IN basket synapse function. However, we cannot rule out the possibility that CCK+/CB1R+ INs are simply less responsive to CCh in the mutants, as we lack the tools to identify CCK+/CB1R+ INs in live tissue for targeted recordings. In contrast, B4gat1M155T/M155T and FkrpP448L/P448L hypomorphic mutants both appear to retain sufficient Dystroglycan glycosylation to maintain normal synapse function.

Increased seizure susceptibility in models of dystroglycanopathy

Human patients with dystroglycanopathy have an increased risk of seizures and epilepsy (Al Dhaibani et al., 2018; Di Rosa et al., 2011; Raphael et al., 2014; Yang et al., 2022), however the underlying cause has yet to be determined. The observed defects in inhibitory basket synapse function suggest that alterations in neuronal circuit inhibition could potentially predispose mutant mice to seizures. To test whether mouse models of dystroglycanopathy exhibit a reduced seizure threshold, we exposed mice to the volatile chemoconvulsant flurothyl and measured the latency to generalized tonic-clonic seizure (TCS) (Egawa et al., 2021).

The latency to TCS was significantly faster in Emx1Cre:Dag1 cKO mice than their littermate controls (a 40.9% reduction on average, Figure 7A), with no difference in seizure latency between sexes in either group (Figure 7—figure supplement 1C). Emx1Cre:Pomt2 cKOs and Dag1cyto/- mutants also had a significantly shorter latency to TCS than littermate controls (42.9% and 33.6% reductions, respectively; Figure 7A), indicating that the mechanism underlying Dystroglycan’s role in seizure susceptibility requires both extracellular glycosylation and intracellular interactions. B4gat1M155T/M155T mutants showed a small but significant reduction (16%) in seizure latency, despite exhibiting no detectable functional deficit by electrophysiology (Figure 6A–C, Figure 7A). Finally, FkrpP448L/P448L mutants showed no significant change in seizure susceptibility (Figure 7A). Thus, the reduction in seizure latency reflects the severity of the synaptic phenotypes across the various models of dystroglycanopathy. These results demonstrate that disruptions in Dystroglycan function, including both its extracellular glycosylation and intracellular interactions, increase sensitivity to seizures.

Figure 7 with 1 supplement see all
Reduced seizure induction threshold in models of dystroglycanopathy.

(A) Quantification of latency (in seconds) to generalized tonic clonic seizure upon exposure to 10% flurothyl delivered at a constant rate. Open points denote statistical outliers. See Supplementary file 1 for Ns. Significance: *=p < 0.05, **=p < 0.01, ***=p < 0.001, NS = p ≥ 0.05.

Discussion

Recent work identified a key role for neuronal Dystroglycan in the establishment and function of CCK+/CB1R+ inhibitory synapses in the forebrain (Früh et al., 2016; Miller and Wright, 2021). Deletion of Dag1 selectively from pyramidal neurons (NeuroD6Cre:Dag1 cKO) led to a near complete loss of CCK+/CB1R+ INs during the first few postnatal weeks. In this study, we sought to better understand how CCK+/CB1R+ IN synapse formation is affected in mouse models that more accurately reflect dystroglycanopathy, in which Dystroglycan function is more broadly affected throughout the CNS (Figures 1 and 2). Using a model that deletes Dag1 throughout the developing forebrain (Emx1Cre:Dag1 cKO) we found that CCK+/CB1R+ INs were present, but the laminar organization of their axon terminals and their ability to form functional basket synapses onto pyramidal neuron cell bodies in the hippocampus was impaired (Figures 36). The inability of CCK+/CB1R+axon terminals to concentrate in the CA1-3 cell body layer began to manifest during the first postnatal week, when dynamic changes in laminar innervation by CCK+/CB1R+ axons normally occur (Figure 4). Furthermore, these mice were found to exhibit a reduced seizure threshold compared to controls, showing for the first time that mouse models of dystroglycanopathy are vulnerable to seizures (Figure 7). Because Emx1Cre (and NestinCre) conditional deletion of Dag1 or Pomt2 leads to widespread loss of functional Dystroglycan in the forebrain in contrast with the previously studied NeuroD6Cre conditional deletion, which targets pyramidal neurons, these models more accurately model dystroglycanopathy.

We found that CCK+/CB1R+ IN synapse formation and function are dependent on proper Dystroglycan glycosylation and appear to correlate with the degree of hypoglycosylation in different mutants. Complete reduction of glycosylation in Emx1Cre:Pomt2 cKO mutants caused the same phenotypes seen in Dystroglycan conditional knockouts (Emx1Cre:Dag1 cKO; Figures 13 and 56), possibly due to the mislocalization of Dystroglycan. The finding that glycosylation is required for Dystroglycan synaptic localization in hippocampal pyramidal cells is similar to a previous finding in retinal photoreceptors in the context of Pomt1 conditional deletion (Rubio-Fernández et al., 2018). In contrast, when Fktn deletion is induced in myotubes β-Dystroglycan localization is unchanged, suggesting that this phenomenon is unique to synaptic Dystroglycan (Beedle et al., 2012). One interpretation is that without matriglycan present to mediate interaction with presynaptic cells, Dystroglycan is no longer concentrated at synaptic sites, implicating it as a synaptic organizer. However, the miswiring of the CCK+/CB1R+ axons could also reduce the likelihood of postsynaptic Dystroglycan encountering a presynaptic axon, discouraging synaptic localization. Conversely, it is possible that glycosylation is required for trafficking to the surface in the first place, however this is less likely given that the levels of β-Dystroglycan were normal in membrane-enriched lysate (Figure 1, Figure 1—figure supplement 2).

A milder reduction in glycosylation (B4gat1M155T/M155T) resulted in a cortical migration phenotype that was restricted to midline (Figure 3—figure supplement 4) and a small reduction in CCK+/CB1R+ axon terminals and synaptic puncta density in CA1 which did not appear to affect synapse function (Figures 3 and 56). The mildest reduction in glycosylation amongst our models was observed in FkrpP448L/P448L mutants, which exhibited normal cortical migration but the same mild defect in CCK+/CB1R+ IN axon targeting and synaptic puncta density observed in B4gat1M155T/M155T mutants (Figures 3 and 56). Together, these three glycosylation mutants illustrate the degree of hypoglycosylation required for neurodevelopmental processes and show that defects in synaptic function only arise in the context of severely reduced glycosylation; the residual Dystroglycan function present in B4gat1M155T/M155T and FkrpP448L/P448L mutants is sufficient for most aspects of brain development. Finally, using Dag1cyto/- mutants that lack the intracellular domain of Dystroglycan, we found that the intracellular domain plays a role in some, but not all, neurodevelopmental processes. The intracellular domain is not required for neuronal migration in neocortex or synapse formation in CA1 (Figures 2 and 5) but is required for the proper targeting of CCK+/CB1R+ IN axons in CA1-3 (Figure 3) and for subsequent CCK+/CB1R+ IN basket synapse function (Figure 6).

Dystroglycan is an essential transsynaptic organizing molecule for CCK+/CB1R+ basket synapses

Synaptogenesis requires multiple distinct steps: (1) synaptic partner recognition, (2) recruitment and assembly of core pre- and post-synaptic machinery, (3) differentiation and maturation of synaptic identity, and (4) synaptic maintenance (Südhof, 2018). Based on data from this study (Figure 4) and previous work from our group and others, mice lacking Dystroglycan exhibit defects in CCK+/CB1R+ IN development at the earliest time point they can be reliably identified (P0-P5), before the peak phase of inhibitory synapse formation (P9), suggesting that Dystroglycan functions at the earliest stages of synaptogenesis such as synaptic partner recognition (Favuzzi et al., 2019). Determining the precise onset of synapse targeting and formation for most IN subtypes, including CCK+/CB1R+INs, is limited by a lack of genetic tools for visualizing and manipulating IN subtypes during developmental stages.

The impairment in CCK+/CB1R+ IN development throughout the forebrain suggests a trans-synaptic role for Dystroglycan (Figure 3, Figure 3—figure supplement 4). The identity of the trans-synaptic binding partner between Dystroglycan-expressing cells and CCK+/CB1R+ INs remains unknown. Our data in Emx1Cre:Pomt2 cKO mice point to a critical role for the glycan chains on Dystroglycan mediating this binding. All proteins that bind to the glycan chains on Dystroglycan do so through at least one Laminin G (LG) domain. There are over 25 LG-domain containing extracellular or transmembrane proteins expressed in the hippocampus. Neurexins, a family of highly alternatively spliced synaptic cell-adhesion molecules (NRXN1-3) which each contain multiple LG domains, bind Dystroglycan in a glycosylation-dependent manner (Boucard et al., 2005; Fuccillo et al., 2015; Reissner et al., 2014; Sugita et al., 2001). The specific splice isoforms of Nrxns that bind Dystroglycan are expressed by CCK+/CB1R+ INs (Fuccillo et al., 2015; Ullrich et al., 1995). Neurexin-3 conditional knockout (targeting all Nrxn3 isoforms) and CRISPR-mediated Dag1 knockout both result in similar synaptic deficits in olfactory bulb and prefrontal cortex (Trotter et al., 2023). While a Dystroglycan knock-in mouse with reduced glycosylation that impairs Neurexin binding (Dag1T190M) shows normal CCK+/CB1R+ synapse formation by immunohistochemistry, the functionality of these synapses was not assessed by electrophysiology (Früh et al., 2016). Similar to B4gat1M155T/M155T and FkrpP448L/P448L mutants, the Dag1T190M mutation does not fully eliminate Dystroglycan glycosylation, and therefore does not rule out the possibility that Neurexins play a role at CCK+/CB1R+ synapses. It is also possible that a yet undescribed Dystroglycan interacting protein is required for initial synapse recognition, and Nrxn-Dag1 interactions are required for subsequent synapse maturation and maintenance only. Indeed, the majority of studies indicate that Neurexins are not required for the initial formation of synapses, but rather regulate the maturation and structural maintenance of synapses after they have formed (Chen et al., 2017; Dudanova et al., 2007; Lin et al., 2023; Missler et al., 2003; Trotter et al., 2023). Interestingly, while Dystroglycan localizes to both PV+ and CCK+/CB1R+ inhibitory basket synapses in CA1, only the CCK+/CB1R+ IN population was affected in the dystroglycanopathy models (Früh et al., 2016). Presumably, PV+ INs have a distinct developmental program independent of Dystroglycan and likely require a different postsynaptic recognition partner.

A role for the dystrophin-glycoprotein complex in CCK+/CB1R+ interneuron development

In brain and muscle tissue, Dystroglycan forms a complex with Dystrophin and several other proteins, collectively known as the Dystrophin Glycoprotein Complex (DGC). Like Dystroglycan, Dystrophin is also expressed throughout the forebrain and is associated with inhibitory synapses in multiple brain regions (Knuesel et al., 1999). Patients with mutations in Dystrophin develop Duchenne Muscular Dystrophy (DMD), and frequently exhibit cognitive impairments in the absence of brain malformations, suggesting a general role for the DGC in synapse development and function (Jagadha and Becker, 1988; Moizard et al., 2000; Naidoo and Anthony, 2020). A mouse model of DMD lacking all neuronal Dystrophin isoforms (mdx) exhibits defects in CCK+/CB1R+ IN synapse development and abnormal innervation in the hippocampus, resembling the innervation pattern we observed in Emx1Cre:Dag1 cKO and Emx1Cre:Pomt2 cKO mice in this study (Krasowska et al., 2014). Since Dystroglycan interacts with Dystrophin through its intracellular domain, we expected to observe similar phenotypes in mice lacking the intracellular domain of Dystroglycan (Dag1cyto/-). However, Dag1cyto/- showed a milder axon targeting defect than Emx1Cre:Dag1 cKO or mdx mice. In addition, IIH6 puncta were normally localized to the somatodendritic compartment in Dag1cyto/- mutants, suggesting that Dystroglycan does not require interactions with Dystrophin for is localization to somatodendritic synapses. However, Dystroglycan’s synaptic localization has not been examined in the mdx mutants. Clearly, additional work is required to better understand the relationship between Dystroglycan and Dystrophin at synapses in the brain.

While the density of CCK+/CB1R+ IN synaptic puncta was normal in Dag1cyto/- mice, synaptic function was impaired to the same level as Emx1Cre:Dag1 cKO and Emx1Cre:Pomt2 cKO mice, and seizure latency was reduced. Given that Dag1cyto/- and B4gat1M155T/M155T mutants show a similar reduction in Dystroglycan glycosylation (Figure 1B–C), our observation that the functional synaptic phenotype is restricted to the Dag1cyto/- mutant reinforces the notion that the intracellular domain of Dystroglycan plays an active role in organizing essential postsynaptic signaling elements. One possibility is that the intracellular domain of Dystroglycan is required to recruit additional postsynaptic scaffolding elements and receptors necessary for CCK+/CB1R+ basket synapse function (Uezu et al., 2019). Importantly, Dag1cyto/- mice did not show a cortical migration phenotype (Figure 2A–D), indicating that the functional synaptic deficits and reduced seizure latency occurred independent of cortical malformation.

Altered inhibitory synapse development and function may contribute to neurological symptoms in dystroglycanopathy

In addition to muscular atrophy and hypotonia, dystroglycanopathy patients often present with central nervous system symptoms. Patients with the most severe forms of dystroglycanopathy (FCMD, Muscle-Eye-Brain disease, and Walker-Warburg Syndrome) exhibit structural changes including hypoplasia of the retina, brainstem and spinal cord, cerebellar cysts, hydrocephalus, Type II lissencephaly, and microcephaly, associated with seizures and cognitive disability (Meilleur et al., 2014; Mercuri et al., 2009). Patients with milder forms of dystroglycanopathy may show cognitive disability and/or seizures without gross brain malformations, suggesting that there may be synaptic deficits independent of early neurodevelopmental processes (e.g. neuronal migration, axon guidance; Mercuri et al., 2009; Yang et al., 2022). The mouse models used in this study recapitulate the full spectrum of brain malformations seen in human patients. Emx1Cre:Dag1 cKO and Emx1Cre:Pomt2 cKO mice show Type II lissencephaly consistent with severe dystroglycanopathy, whereas B4gat1M155T/M155T and FkrpP448L/P448L mutants have relatively normal cortical development consistent with mild dystroglycanopathy. Mutations in any of the genes involved in the glycosylation of Dystroglycan can result in dystroglycanopathy with seizures, but the incidence and severity of seizures is higher in patients with brain malformations (Mercuri et al., 2009; Wang et al., 2017; Yang et al., 2022).

Mice have been used to model dystroglycanopathy for decades; however, to our knowledge the present study is the first to investigate seizure susceptibility in mouse models of dystroglycanopathy. It is probable that the CCK+/CB1R+ interneuron axon targeting and synapse phenotypes in the mouse models described in the present study contribute to their seizure susceptibility and open the possibility that defective inhibitory synaptic signaling mechanisms may underlie seizures in dystroglycanopathy patients. Although severe neuronal migration phenotypes In Emx1Cre:Dag1 cKO and Emx1Cre:Pomt2 cKO mice may contribute to seizure activity, our observation that Dag1cyto/- mutants showed both abnormal CCK+/CB1R+synaptic function and reduced seizure latency, with intact cortical migration, indicates that the seizure phenotype is likely associated with synaptic defects. Supporting these results, CCK+/CB1R+ interneurons in the hippocampus are selectively lost in models of temporal lobe epilepsy with recurrent seizures induced by pilocarpine. CCK+/CB1R+ axons in CA1-3 begin to degenerate within hours of status epilepticus, whereas PV+ INs are unaffected in this model (Whitebirch et al., 2023; Wyeth et al., 2010).

While our B4gat1M155T/M155T mutants showed only a slightly reduced seizure latency, the mutants experienced more severe seizures than the other mouse models, resulting in death in 50% of cases (4/8 mutants compared to 0/6 fatalities among littermate controls) (Figure 7—figure supplement 1A). Flurothyl-induced seizures are typically generalized forebrain seizures; however in seizure-prone mouse models or in mice exposed to higher concentrations of flurothyl, mice can experience a suppression of brainstem oscillations followed by sudden death (Gu et al., 2022; Kadiyala et al., 2016). The B4gat1M155T/M155T mutation was originally identified based on a hindbrain axon guidance phenotype, suggesting they may have currently unknown defects in brainstem development or circuitry that could render them more susceptible to fatal brainstem seizures (Wright et al., 2012). Because the Dag1 and Pomt2 mutants are forebrain-specific conditional knockouts, (Figure 1—figure supplement 1A), we would not anticipate abnormal axon guidance in the brainstem or hindbrain of these mutants. Further research on the nature and progression of seizures observed in mouse models may have a profound impact on our understanding of dystroglycanopathy and potential therapeutic interventions.

Potential therapeutics for the restoration of synapse function in patients with dystroglycanopathy

Most patients with dystroglycanopathy present with mutations in one of the 19 genes required for the glycosylation of Dystroglycan, resulting in hypoglycosylated Dystroglycan. We have demonstrated that a mild reduction in the glycosylation of Dystroglycan, as seen in FkrpP448L/P448L and B4gat1M155T/M155T mutants, does not significantly disrupt synapse function. This suggests that glycosylation may not need to be restored to wild-type levels in order to achieve normal synapse function. Gene replacement therapy may be well suited to treat certain forms of dystroglycanopathy by rescuing glycosylation. AAV-mediated delivery of fully functional glycosyltransferases has been shown to significantly improve muscle pathology and function in dystrophic mice, however synaptic phenotypes have not been examined (Kanagawa, 2021). Supplementation with (CDP)-ribitol, which is synthesized by Crppa (previously known as ISPD), can restore functional Dystroglycan glycosylation and improve muscle function in mouse models with hypomorphic mutations in Crppa or Fkrp (Cataldi et al., 2018). In mice lacking functional Crppa or Fkrp in skeletal muscle, (CDP)-ribitol can further enhance the therapeutic impact of gene restoration (Cataldi et al., 2020). However, whether (CDP)-ribitol treatment can improve Dystroglycan function in other models of dystroglycanopathy, or is capable of restoring Dystroglycan glycosylation and synaptic function in the nervous system, remains untested.

Conclusions

We demonstrate that Dystroglycan is critical for the postnatal development of CCK+/CB1R+ interneuron axon targeting and synapse formation/function in the hippocampus of severe mouse models of dystroglycanopathy. Extracellular glycosylation of Dystroglycan and intracellular interactions involving the cytoplasmic domain are both essential for Dystroglycan’s synaptic organizing role. Mice with a partial reduction in glycosylation have relatively normal CCK+/CB1R+ interneuron axon targeting and synapse function, suggesting that even a partial restoration of glycosylation may have some therapeutic benefit. These findings suggest that CCK+/CB1R+ interneuron axon targeting defects may contribute to cognitive impairments and seizure susceptibility in dystroglycanopathy.

Materials and methods

Animal husbandry

Request a detailed protocol

All animals were housed and cared for by the Department of Comparative Medicine (DCM) at Oregon Health and Science University (OHSU), an AAALAC-accredited institution. Animal procedures were approved by OHSU Institutional Animal Care and Use Committee (Protocol # IS00000539), adhered to the NIH Guide for the care and use of laboratory animals, and provided with 24 hr veterinary care. Animal facilities are regulated for temperature and humidity and maintained on a 12 hr light-dark cycle and were provided food and water ad libitum. Animals older than postnatal day 6 (P6) were euthanized by administration of CO2, animals <P6 were euthanized by rapid decapitation.

Mouse strains and genotyping

Request a detailed protocol

The day of birth was designated postnatal day 0 (P0). Ages of mice used for each analysis are indicated in the figure and figure legends. Mouse strains used in this study have been previously described and were obtained from Jackson Labs, unless otherwise indicated (Table 1; Chan et al., 2010; Cohn et al., 2002; Goebbels et al., 2006; Gorski et al., 2002; Hu et al., 2011; Peron et al., 2015; Satz et al., 2009; Tronche et al., 1999; Wright et al., 2012). Dag1+/- mice were generated by crossing the Dag1flox/flox line to a Sox2Cre line to generate germline Dag1Δ/+ mice hereafter referred to as Dag1+/- as the resultant transcript is nonfunctional. These mice were thereafter maintained as heterozygotes. Breeding schemas are as described in Table 2. Where possible, mice were maintained on a C57BL/6J background. Dag1cyto/- mice occurred at a frequency lower than Mendelian, suggesting that a proportion of progeny die embryonically. To increase viability of pups, the Dag1cyto line was outcrossed to a CD-1 background for one generation. The B4gat1 line has a mixed genetic background: it was founded on a C3H/He background and then crossed on to C57BL/6J for future generations. Genomic DNA extracted from toe or tail samples (Quanta BioSciences) was used to genotype animals. Primers for genotyping can be found on the JAX webpage or originating article. Dag1+/- mice were genotyped with the following primers: CGAACACTGAGTTCATCC (forward) and CAACTGCTGCATCTCTAC (reverse). For each mouse strain, littermate controls were used for comparison with mutant mice. For all experiments, unless otherwise noted, mice of both sexes were used indiscriminately. See Supplementary file 1 for a summary of sexes used in each experiment.

Table 1
Mouse strains.
Common nameStrain nameReferenceStock #
Dag1FloxB6.129(Cg)-Dag1tm2.1Kcam/JCohn et al., 2002009652
Dag1cytoN/ASatz et al., 2009N/A
Pomt2FloxPOMT2tm1.1Hhu/JHu et al., 2011017880
B4gat1M155TB6(C3)-B4GAT1m1Ddg/JWright et al., 2012022018
FkrpP448LC57BL/6NJ-Fkrpem1Lgmd/JChan et al., 2010034659
R26LSL-H2B-mCherryB6.Gt(ROSA)26Sortm1.1KsvoPeron et al., 2015023139
Emx1CreB6.129S2-Emx1tm1(cre)Krj/JGorski et al., 2002005628
NestinCreB6.Cg-Tg(Nes-cre)1Kln/JTronche et al., 1999003771
NEXCreNeuroD6tm1(cre)KanGoebbels et al., 2006MGI:4429523
Sox2CreB6N.Cg-Edil3Tg(Sox2-cre)1Amc/JHayashi et al., 2002014094
Table 2
Breeding schemes.
Breeding SchemeControl GenotypeMutant Genotype
Emx1Cre/+;Dag1+/- x Dag1Flox/FloxEmx1Cre/+;Dag1Flox/+Emx1Cre/+;Dag1Flox/-
NestinCre/+;Dag1+/- x Dag1Flox/FloxNestinCre/+;Dag1Flox/+NestinCre/+;Dag1Flox/-
NEXCre/+;Dag1+/- x Dag1Flox/FloxNEXCre/+;Dag1Flox/+NEXCre/+;Dag1Flox/-
Emx1Cre/+;Pomt2Flox/+ x Pomt2Flox/FloxEmx1Cre/+;Pomt2Flox/+Emx1Cre/+;Pomt2Flox/Flox
Dag1cyto/+ x Dag1+/-WTDag1cyto/-
B4gat1M155T/+ x B4gat1M155T/+WTB4gat1M155T/M155T
FkrpP448L/+ x FkrpP448L/+WTFkrpP448L/P448L

Perfusions and tissue preparation

Request a detailed protocol

Brains from mice younger than P15 were dissected and drop fixed in 5 mLs of 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS) overnight for 18–24 hr at 4 °C. Mice P15 and older were deeply anesthetized using CO2 and transcardially perfused with ice cold 0.1 M PBS for two minutes to clear blood from the brain, followed by 15 mL of ice cold 4% PFA in PBS. After perfusion, brains were dissected and post-fixed in 4% PFA for 30 min at room temperature. Brains were rinsed with PBS, embedded in 4% low-melt agarose (Fisher cat. no. 16520100), and sectioned at 50 μm using a vibratome (VT1200S, Leica Microsystems Inc, Buffalo Grove, IL) into 24-well plates containing 1 mL of 0.1 M PBS with Sodium Azide.

Immunohistochemistry

Request a detailed protocol

Single and multiple immunofluorescence detection of antigens was performed as follows: free-floating vibratome sections (50 μm) were briefly rinsed with PBS, then blocked for 1 hr in PBS containing 0.2% Triton-X (PBST) plus 2% normal goat or donkey serum. Sections were incubated with primary antibodies (Table 3) diluted in blocking solution at 4 °C for 48–72 hr. For staining of Dystroglycan synaptic puncta, an antigen retrieval step was performed prior to incubation in primary antibody. Briefly, sections were incubated in sodium citrate solution for 15 min at 95°C in a water bath followed by 15 minutes at room temperature. Following incubation in primary antibody, sections were rinsed with PBS then washed with PBST three times for 20 min each. Sections were then incubated with a cocktail of secondary antibodies (1:500, Alexa Fluor 488, 546, 647) in blocking solution overnight at room temperature. Sections were washed with PBS three times for 20 min each and counterstained with Hoechst 33342 (1:10,000, Life Technologies, Cat# H3570) for 20 min to visualize nuclei. Finally, sections were mounted on slides using Fluoromount-G (SouthernBiotech) and sealed using nail polish.

Table 3
Primary antibodies used for immunohistochemistry.
TargetHost speciesDilutionSourceCatalog #RRID
α-Dystroglycan (IIH6C4)Mouse1:250Millipore05–593AB_309828
β-DystroglycanMouse1:50Leica BiosystemsNCL-b-DGAB_442043
CB1RGuinea pig1:1000Synaptic Systems258–104AB_2661870
Cux1Rabbit1:500Santa Cruz Biotechsc-13024AB_2261231
LamininRabbit1:1000Sigma-AldrichL9393AB_477163
NECAB1Rabbit1:500Sigma-AldrichHPA023629AB1848014
NECAB2Rabbit1:500Proteintech12257–1-APAB_2877841
NeuNMouse1:250MilliporeMAB377AB_2298772
ParvalbuminRabbit1:1000SwantPV27AB_2631173
ParvalbuminMouse1:50Swant235AB_10000343
SomatostatinRabbit1:2000Peninsula LabsT-4103AB_518614
Tbr1Rabbit1:500MilliporeAB10554AB_10806888
VGATRabbit1:500Synaptic Systems131–003AB_887869
VGATGuinea Pig1:500Synaptic Systems131–005AB_1106810
VGlut3Rabbit1:1000Synaptic Systems135–203AB_887886
VIPRabbit1:1000ImmunoStar20077AB_572270

Microscopy

Request a detailed protocol

Imaging was performed on either a Zeiss Axio Imager M2 fluorescence upright microscope equipped with an Apotome.2 module or a Zeiss LSM 980 laser scanning confocal build around a motorized Zeiss Axio Observer Z1 inverted microscope with a Piezo stage. The Axio Imager M2 uses a metal halide light source (HXP 200 C), Axiocam 506 mono camera, and 10X/0.3 NA EC Plan-Neofluar, 20X/0.8 NA Plan-Apochromat objectives. The LSM 980 confocal light path has two multi-alkali PMTs and two GaAsP PMTs for four track imaging. Confocal images were acquired using a 63X/1.4 NA Plan-Apochromat Oil DIC M27 objective. Z-stack images were acquired and analyzed offline in ImageJ/FIJI (Schindelin et al., 2012) or Imaris 9.8 (Oxford Instruments). Images used for quantification between genotypes were acquired using the same exposure times. Brightness and contrast were adjusted in FIJI to improve visibility of images for publication. Figures were composed in Adobe Illustrator 2023 (Adobe Systems).

Image quantification

For imaging experiments, 4–8 images were acquired from 2 to 4 coronal sections per animal, and at least three animals per genotype were used for analysis.

Cortical lamination

Request a detailed protocol

Images of somatosensory cortex were acquired using a 10X objective on a Zeiss Axio Imager M2. 4 μm z-stacks covering 16 μm were acquired and multiple tiles were stitched together. Maximum projections were used for analysis. In FIJI, the straight line tool with a 300 μm line width was used to measure the fluorescence profile from corpus callosum to pial surface. Background fluorescence was determined as the average fluorescence of the 20 darkest pixels; background was then subtracted from all points. The cortical distance was broken into 10 bins and average fluorescence within each bin was compared between genotypes.

Hippocampal CA1 CB1R and PV distribution

Request a detailed protocol

Images of dorsal hippocampal CA1 were acquired using a 20X objective on a Zeiss Axio Imager M2. Maximum projection images of 0.6 μm z-stacks covering 9 μm were analyzed in FIJI. The straight line tool with a 300 μm line width was used to measure the fluorescence profile within SO, SP, and SR of CA1, avoiding Parvalbumin+ cell bodies. Background fluorescence was determined as the average fluorescence of the 50 darkest pixels; background was then subtracted from all points. The thickness of SP was determined using Hoechst fluorescence. Average fluorescence within SO/SP/SR was compared between genotypes.

Interneuron cell counts in CA1

Request a detailed protocol

Images of dorsal hippocampal CA1 were acquired using a 10X objective on a Zeiss Axio Imager M2. Maximum projection images of 4 μm z-stacks covering 40 μm were analyzed in FIJI. Immunolabeled NECAB1/NECAB2/PV cell bodies were counted if they were within 100 μm of stratum pyramidale. The freehand line tool was used to measure the length of stratum pyramidale. Cell number was normalized to the length of stratum pyramidale present in the analyzed region.

Hippocampal CB1R/PV/VGAT density and co-localization

Request a detailed protocol

Images of dorsal hippocampal CA1 were acquired using a 63X objective on a Zeiss LSM 980. 0.2 μm z-stacks covering 3 μm were analyzed in Imaris. Hoechst fluorescence was used to determine the bounds of SP. The Imaris Spots function was used to determine the location of synaptic puncta in 3-dimensional space. Synaptic puncta were deemed to be co-localized if they were within 1 μm of each other.

Western blot

Request a detailed protocol

Cortex or hippocampus was dissected and solubilized in 1 mL of lysis buffer containing 100 mM NaCl, 50 nM Tris, 2.5 mM CaCl2, 1% Triton X-100, 1% n-Octyl-β-D-glucopyranoside, and protease inhibitors. Lysate was incubated at 4 °C for 1 hr and then spun at 12,500 g for 25 min. Supernatant containing 3000 μg (cortex) or 2000 μg (hippocampus) of protein (as determined by Pierce BCA Protein Assay) was applied to agarose-bound Wheat Germ Agglutinin (WGA) (Vector Labs) overnight at 4 °C. Beads were washed 3 times in TBS and boiled in 1X LDS sample buffer with 2-Mercaptoethanol (1:100) for 5 min. Samples were run on a 4–15% gradient polyacrylamide gel at 100 V for 75 min and then transferred to a PVDF membrane (100 V for 100 min). For immunoblotting, membranes were blocked in 5% milk TBST and then incubated overnight at 4 °C in 5% milk TBST containing primary antibody. Antibodies used: α-Dystroglycan (IIH6C4) (Millipore cat. no. 05–593, RRID: AB_309828, mouse IgM, 1:500), MANDAG2 (DSHB cat. no. 7D11, RRID: AB_2211772, mouse IgG1, 1:500), β3-tubulin (Cell Signaling Technology cat. no. 5568, RRID: AB_10694505, rabbit, 1:2000). Membranes were washed 3 times in TBST for 15 minutes each and incubated on fluorescent IRDye secondary antibody (1:10,000, LI-COR) in 5% milk TBST for 1 hr at room temperature. Membranes were imaged using a LI-COR Odyssey CLx 0918 imager and signal analyzed using LI-COR Image Studio Lite version 5.2.

Electrophysiology

Request a detailed protocol

For acute slice preparation, mice were deeply anesthetized in 4% isoflurane and subsequently injected with a lethal dose of 2% 2, 2, 2-Tribromoethanol in sterile water followed by transcardial perfusion with 10 mL ice cold cutting solution containing the following (in mM): 93 NMDG, 2.5 KCl, 1.2 NaH2PO4, 30 NaHCO3, 20 HEPES, 24 glucose, 5 Na Ascorbate, 2 Thiourea, 3 Na Pyruvate, 13 N-Acetyl Cysteine, 1 Kynurenic acid, 10 MgSO4, 0.5 CaCl2; pH 7.3, 300–340 mmol/kg. After rapid decapitation, the brain was briefly submerged in ice cold cut solution bubbled with carbogen (95% oxygen, 5% CO2) and then sectioned into 300 μm sagittal sections (Leica VT1200S vibratome) in bubbled ice-cold cut solution. Slices were recovered in 37 °C cut solution, bubbled, for 15 min followed by 1 hr in room temperature recording ACSF (containing, in mM: 125 NaCl, 25 NaHCO3, 1.25 NaH2PO4, 3 KCl, 25 D-Glucose, 2 CaCl2, 1 MgCl2) with an osmolarity of 310–320 mmol/kg and supplemented with 1.5 mM Na Ascorbate, bubbled.

CA1 pyramidal cells were patched in whole cell configuration using 3–5 MΩ borosilicate glass pipettes filled with high chloride internal solution containing the following (in mM): 125 CsCl, 2.5 MgCl2, 0.5 EGTA, 10 HEPES, 2 Mg-ATP, 0.3 Na-GTP, 5 QX-314; pH 7.2, 300 mmol/kg. Pipettes were wrapped in parafilm to reduce capacitive currents. Cells were voltage clamped at –70 mV and continuously superfused with 2–3 mL/min bubbled recording ACSF (310–320 mmol/kg) containing 10 μM NBQX to block excitatory transmission. Recordings were performed at 34 °C. After 5 min of spontaneous IPSC (sIPSC) recording, 10 μM Carbachol was added to the perfusate and another 5 min of sIPSC were recorded. Slices were discarded after exposure to Carbachol. Signals were amplified with an AxoPatch 200B amplifier (Molecular Devices), low-pass filtered at 5 kHz, and digitized and sampled at 10 kHz with a NIDAQ analog-to-digital board (National Instruments). Data were acquired and analyzed using a custom script in Igor Pro 8 (Wavemetrics; https://github.com/jnjahncke/mini_analysis copy archived at Jahncke, 2023). A hyperpolarizing step of –10 mV was applied before each sweep to monitor input resistance, series resistance, and measure cell capacitance. Series resistance was not compensated and was maintained below 20 MΩ. Cells were excluded if series resistance changed by more than 25%.

To calculate the proportion of cells that responded to Carbachol, cells were sorted into ‘responsive’ and ‘non-responsive’ categories. Cells were categorized as responsive if sIPSC frequency increased by 20% or more with the addition of Carbachol. If sIPSC frequency in a cell changed by less than 20% or less than 0.5 Hz it was deemed non-responsive.

Flurothyl seizure induction

Request a detailed protocol

Mice aged P40-P55 were used for the flurothyl-induced seizure susceptibility assay to determine seizure threshold. Briefly, mice were placed in an enclosed glass chamber equipped with a vaporization chamber out of reach of the mouse. Volatile liquid 10% Bis (2,2,2-Trifluorotheyl) Ether (Millipore Sigma cat. no 287571) in 95% EtOH was delivered to the vaporization chamber at a rate of 6 mL/hr. Seizure latency was determined as the amount of time until generalized tonic-clonic seizure (TCS). Upon exhibiting TCS, animals were immediately removed from the chamber and returned to their home cage, whereupon seizures ceased rapidly. Sample size was determined using power analysis as described below. The Emx1Cre:Dag1 experimental groups were powered sufficiently to determine sex differences. Because no sex difference was found (Figure 7—figure supplement 1C), sexes were pooled for the remaining experiments. For statistical tests, outliers were excluded. Outliers were calculated as follows: first, the interquartile range (IQR) was calculated and multiplied by 1.5. This 1.5*IQR value was subtracted from the 25% quartile (Q1) and added to the 75% quartile (Q3). Points outside of the range Q1 - 1.5*IQR <x < Q3+1.5*IQR were categorized as outliers and indicated as such on all graphs. This was done to remove bias from extreme outliers observed in this experiment.

Statistical analysis

Request a detailed protocol

Phenotypic analyses were conducted using tissue collected from at least three mice per genotype from at least two independent litters. The number of mice and replicates used for each analysis (‘N’) are indicated in Supplementary file 1. Samples from each mouse were only used for one technical replicate. Power analysis using pilot data was used to determine samples sizes with α=0.05 and β=0.80. Phenotypes were indistinguishable between male and female mice and were analyzed together. Although experimenters were blind to genotype during analysis, in many cases highly penetrant phenotypes revealed the genotypes of the mice and no blinding could be faithfully performed. Unless otherwise stated, no data was excluded from analysis. For comparisons between two groups, significance was determined using a two-tailed Students t-test. For comparisons between more than two groups, significance was determined using a two-way ANOVA with Tukey HSD post-hoc analysis. Statistical significance was set at α=0.05 (p<0.05) and data presented as means ± SEM. Individual statistical tests and specific p-values are reported in Supplementary file 2. Statistical analyses and data visualization were performed in R (version 4.0.2).

Data availability

All data generated or analyzed during the study are included in the manuscript and supporting files; Ns for experiments are provided in Supplementary file 1 and statistical tests are included in Supplementary file 2.

References

Peer review

Reviewer #1 (Public Review):

This important study from Jahncke et al. demonstrates inhibitory synaptic defects and elevated seizure susceptibility in multiple models of dystroglycanopathy. A strength of the paper is the use of a wide range of genetic models to disrupt different aspects of dystroglycan protein or glycosylation in forebrain neurons. The authors use a combination of immunohistochemistry and electrophysiology to identify cellular migration, lamination, axonal targeting, synapse formation/function, and seizure phenotypes in forebrain neurons. This is an elegant study with extensive data supporting the conclusions. The role of dystroglycan and the dystrophin glycoprotein complex (DGC) in cellular migration and synapse formation are of broad interest.

A strength of this paper is the use of several transgenic mouse lines with mutations in genes involved in glycosylation of dystroglycan. Knockout of POMT2 abolishes the majority of dystroglycan glycosylation, while point mutations in B4GAT and FKRP presumably produce more minor changes in glycosylation. This is a powerful approach to investigate the role of glycosylation in dystroglycan function.

https://doi.org/10.7554/eLife.87965.3.sa1

Reviewer #2 (Public Review):

The manuscript by Jahncke and colleagues is centered on the CCK+ synaptic defects that are a consequence of Dystroglycanopathy and/or impaired dystroglycan-related protein function. The authors use conditional mouse models for Dag1 and Pomt2 to ablate their function in mouse forebrain neurons and demonstrate significant impairment of CCK+/CB1R+ interneuron (IN) development in addition to being prone to seizures. Mice lacking the intracellular domain of Dystroglycan have milder defects, but impaired CCK+/CB1R+ IN axon targeting. The authors conclude that the milder dystroglycanopathy is due to the partially reduced glycosylation that occurs in the milder mouse models as opposed to the more severe Pomt2 models. Additionally, the authors postulate that inhibitory synaptic defects and elevated seizure susceptibility are hallmarks of severe dystroglycanopathy and are required for the organization of functional inhibitory synapse assembly.

The manuscript is overall, fairly well-written and the description of the phenotypic impact of disruption of Dystroglycan forebrain neurons (and similar glycosyltransferase pathway proteins) demonstrate impairment in axon targeting and organization. There are some questions with regards to interpretation of some of the results from these conditional mouse models. The study is mostly descriptive, and some validation of subunits of the dystroglycan-glycoprotein complex and laminin interactions would go towards defining the impact of disruption of dystroglycan's function in the brain. The statistics and basic analysis of the manuscript appear to be appropriate and within parameters for a study of this nature. Some clarification between the discrepancies between the Walker Warburg Syndrome (WWS) patient phenotypes and those observed in these conditional mouse models is warranted. This manuscript has the potential to be impactful in the Dystroglycanopathy and general neurobiology fields.

The authors have made significant improvements to address my concerns in this resubmission and the previous critiques of the other reviewers since the prior submission. The work is comprehensive in scope and the statistics are appropriate where required. I believe the conclusions to be valid for this study and I don't have any additional recommendations. I believe this work to be of importance to the Dystroglycanopathy and neurobiology fields.

https://doi.org/10.7554/eLife.87965.3.sa2

Reviewer #3 (Public Review):

The study presents a systematic analysis of how a range of dystroglycan mutations alter CCK/CB1 axonal targeting and inhibition in hippocampal CA1 and impact seizure susceptibility. The study follows up on prior literature identifying a role for dystroglycan in CCK/CB1 synapse formation. The careful assay includes comparison of 5 distinct dystroglycan mutation types known to be associated with varying degrees of muscular dystrophy phenotypes: a forebrain specific Dag1 knockout in excitatory neurons at 10.5, a forebrain specific knockout of the glycosyltransferase enzyme in excitatory neurons, mice with deletion of the intracellular domain of beta-Dag1 and 2 lines with missense mutations with milder phenotypes. They show that forebrain glutamatergic deletion of Dag1 or glycosyltransferase alters cortical lamination while lamination is preserved in mice with deletion of the intracellular domain or missense mutation. The study extends prior works by identifying that forebrain deletion of Dag1 or glycosyltransferase in excitatory neurons impairs CCK/CB1 and not PV axonal targeting and CB1 basket formation around CA1 pyramidal cells. Mice with deletion of the intracellular domain or missense mutation show

limited reductions in CCK/CB1 fibers in CA1. Carbachol enhancement of CA1 IPSCs was reduced both in forebrain knockouts. Interestingly, carbachol enhancement of CA1 IPSCs was reduced when the intracellular domain of beta-Dag1was deleted, but not I the missense mutations, suggesting a role of the intracellular domain in synapse maintenance. All lines except the missense mutations , showed increased susceptibility to chemically induced behavioral seizures. Together, the study, is carefully designed, well controlled and systematic. The results advance prior findings of the role for dystroglycans in CCK/CB1 innervations of PCs by demonstrating effects of more selective cellular deletions and site specific mutations in extracellular and intracellular domains.

Prior concerns regarding CCK/CB1 cell numbers and potential changes in basal synaptic inhibition are addressed in the revision.

https://doi.org/10.7554/eLife.87965.3.sa3

Author response

The following is the authors’ response to the original reviews.

We thank the reviewers for their service and are pleased to see that they were positive about the overall study. The reviewers provided several very good suggestions that we feel have improved the revised manuscript. In response to their suggestions, we have added four new figures of additional data (Figure 1, Supplement 2; Figure 2, Supplement 2; Figure 3, Supplements 1 and 2) in this revision. We have addressed the specific review comments/suggestions point-by-point below. Text changes in the manuscript are indicated in red with line numbers indicated.

Public Reviews:

Reviewer #1 (Public Review):

This important study from Jahncke et al. demonstrates inhibitory synaptic defects and elevated seizure susceptibility in multiple models of dystroglycanopathy. A strength of the paper is the use of a wide range of genetic models to disrupt different aspects of dystroglycan protein or glycosylation in forebrain neurons. The authors use a combination of immunohistochemistry and electrophysiology to identify cellular migration, lamination, axonal targeting, synapse formation/function, and seizure phenotypes in forebrain neurons. This is an elegant study with extensive data supporting the conclusions. The role of dystroglycan and the dystrophin glycoprotein complex (DGC) in cellular migration and synapse formation are of broad interest.

• A strength of this paper is the use of several transgenic mouse lines with mutations in genes involved in glycosylation of dystroglycan. Knockout of POMT2 abolishes the majority of dystroglycan glycosylation, while point mutations in B4GAT and FKRP presumably produce more minor changes in glycosylation. This is a powerful approach to inves5gate the role of glycosylation in dystroglycan function. However, the authors do not address how mutations in these genes may affect glycosylation or expression of proteins other than dystroglycan. It is possible, even likely, that some of the phenotypes observed are due to changing glycosylation in any number of other proteins. The paper would be strengthened by addressing this possibility more directly.

We are glad to see that the reviewer appreciated the range of transgenic models used to define the role of Dag1 glycosylation. It is certainly possible that glycosylation of proteins other than Dag1 is affected by deletion of Pomt2, B4Gat1 and/or FKRP. Indeed, Cadherin and Plexin proteins undergo Omannosylation in the brain. However, recent work has shown that these proteins are not dependent on Pomt1/2 for their O-mannosylation, and use an alternative glycosylation pathway. Therefore, they unlikely to contribute to the phenotypes we observed in our Pomt2, B4Gat1 and/or FKRP mutants. Furthermore, we did not observe any phenotypes in these models that was not also observed in the Dag1 conditional knockouts. We have clarified this point in the results section (lines 117-121) with additional references, and added the caveat that Pomt2, B4gat1, and Fkrp could play a role in the glycosylation of proteins other than Dag1.

• It would be helpful to have a more clear description of how dystroglycan glycosylation is altered in B4GAT1M155T or FKRPP448L mice. For example, Figure 1 makes it appear that the distal sugar moieties are missing, however, the IIH6 antibody, which binds to terminal matriglycan repeats on the glycan chain, recognizes dystroglycan in these mutants.

We apologize for the confusion caused by our schematic in Figure 1. We have adjusted the opacity of the schematic in Figure 1A to better illustrate that the matriglycan chain is s5ll present, albeit at reduced levels, in the B4Gat1 and FKRP mutants. In addition, this is directly shown in the western blot in Figure 1B.

• In Figure 1, the authors use the IIH6 antibody, which recognizes the terminal portion of the dystroglycan glycan chain, to label dystroglycan in the hippocampus. As expected, Emx1Cre,POMT2cKO mice, which lack glycosylation of dystroglycan, do not show any labelling. However, this experiment does not reveal anything about dystroglycan expression, only that the IIH6 antibody no longer recognizes dystroglycan. It would be very helpful in interpreting the later results to know whether the level and pattern of dystroglycan expression is normal or absent in the POMT2cKO mice, perhaps using another antibody that does not target the glycosylated region. For example, figure 3 shows reduced axon targeting to the cell body layer in POMT2cKO, however, it is unclear whether this is due to absence/mislocalization of dystroglycan at the cell surface, or if dystroglycan expression is normal, but glycosylation is directly required for axon targeting.

Addressed in the “Recommendation for Authors” section below

• In Figures 3 and 5, the authors use CB1R labelling to measure axon targeting and synapses formation. However, it is not clear how the authors measure axon targeting and synapses number separately using the same CB1R antibody. In addition, figure 3 shows reduced CB1R labelling in Dag1cyto pyramidal cell layer, but Figure 5 shows no change in CB1R labelling in the same mice. These results would appear to be contradictory.

In Figure 3, the data reflects fluorescent intensity of CB1R+ axons measured across the en5re hippocampal depth. In contrast, the synapse number in Figure 5 is measured as VGat+ and CB1R+ puncta (axonal swellings) within the pyramidal cell layer (SP). The discrepancy between these measurements in the Dag1Cyto mutants likely reflects a change in the distribution of the synaptic contacts in SP (ie: increased contacts in the upper portion of the SP relative to the bottom). This is clarified in the text, lines 315-319.

• The authors measure spontaneous IPSCs (sIPSC) in CA1 pyramidal neurons to measure inhibitory synaptic function. This measure assesses inhibitory synaptic input from all sources, but dystroglycan mutations primarily impairs synapses arising from CCK+/CB1R interneurons, leaving synapses arising from PV or other interneurons relatively unchanged. To assess changes in CCK+/CB1R interneurons the authors apply the cholinergic receptor agonist Carbachol (which selectively activates CCK+/CB1R interneurons) and measure the change in sIPSC amplitude and frequency. While this is an interesting and reasonable experiment, the observed effects could be due to altered carbachol sensitivity in the transgenic mice. Control experiments showing that the effect of Carbachol on excitability of CCK+/CB1R interneurons is similar across mouse lines is missing.

The reviewer is correct that we did not show that CCK/CB1R+ interneurons have the same sensitivity to CCh in controls and the various mutants. Indeed, this is something we have struggled with over the course of the study, and is an inherent limitation of the current study. Unfortunately, these cells are relatively sparse in the CA1, and therefore patching onto presumptive CCK/CB1R+ INs at random to test this directly is not feasible. There are also no genetic or viral tools that we are aware of at this time to fluorescently label these cells for targeted recordings (this would need to be a Cre-independent transgenic mouse line since we are using Cre to delete Dag1 and Pomt2). We tried to assess this by measuring c-fos immunohistochemistry staining as a proxy for activity in response to CCh. Briefly, we incubated acute slices with NBQX, SR95531, and Kynurenic Acid to block synaptic activity, and added CCh in the bath for 30, 60, and 90 minutes to induce CCK/CB1R+ INs firing. Slices were then fixed and stained for c-fos and NECAB1 to identify the CCK/CB1R+ interneurons.

Unfortunately, we had a very difficult time imaging these slices, and we were not confident in our ability to localize c-fos+/NECAB1+ cells. We have clarified that this is an inherent limitation to the study in the text, lines 394-396.

• Earlier work has shown that selective deletion of dystroglycan from pyramidal neurons produces near complete loss of CCK+/CB1R interneurons and synapse formation, a more severe deficit than observed here using a more widespread Cre-driver. This finding is surprising, as generally more wide-spread gene deletion results in more severe, not less severe, phenotypes. The authors make the reasonable claim that more wide-spread gene deletion better mimics human pathologies. However, possible speculation on why this is the case for dystroglycan could provide insight into the nature of CNS deficits in different forms of dystroglycanopathies.

The reviewer is correct that previous work from both our lab and others have shown that deletion of Dag1 from only pyramidal neurons with NEX-cre leads to a complete loss of CCK/CB1R+ INs, and is thus more severe than the phenotype seen with the broader deletion of Dag1 with Emx1-Cre. We were also surprised by this result, so we also generated Dag1;Nestin-Cre mice. These mice show an iden5cal phenotype as the Dag1;Emx1-Cre mutants (new data; Figure 3, Supplement 1; text lines 226-233). This makes us confident in the validity of the Dag1;Emx-Cre mutants with regards to modeling the human disease. We do not know why the NEX-Cre line shows a more severe phenotype; it is possible that this is due to an unknown epistatic interaction between Dag1 and NEX-Cre.

Reviewer #2 (Public Review):

The manuscript by Jahncke and colleagues is centered on the CCK+ synaptic defects that are a consequence of Dystroglycanopathy and/or impaired dystroglycan-related protein function. The authors use conditional mouse models for Dag1 and Pomt2 to ablate their function in mouse forebrain neurons and demonstrate significant impairment of CCK+/CB1R+ interneuron (IN) development in addition to being prone to seizures. Mice lacking the intracellular domain of Dystroglycan have milder defects, but impaired CCK+/CB1R+ IN axon targeting. The authors conclude that the milder dystroglycanopathy is due to the par5ally reduced glycosylation that occurs in the milder mouse models as opposed to the more severe Pomt2 models. Additionally, the authors postulate that inhibitory synaptic defects and elevated seizure susceptibility are hallmarks of severe dystroglycanopathy and are required for the organization of functional inhibitory synapse assembly.

The manuscript is overall, fairly well-written and the description of the phenotypic impact of disruption of Dystroglycan forebrain neurons (and similar glycosyltransferase pathway proteins) demonstrate impairment in axon targeting and organization.

There are some questions with regards to interpretation of some of the results from these conditional mouse models.

• The study is mostly descriptive, and some validation of subunits of the dystroglycanglycoprotein complex and laminin interactions would go towards defining the impact of disruption of dystroglycan's function in the brain.

Addressed in the “Recommendation for Authors” section below

• The statistics and basic analysis of the manuscript appear to be appropriate and within parameters for a study of this nature.

• Some clarification between the discrepancies between the Walker Warburg Syndrome (WWS) patient phenotypes and those observed in these conditional mouse models is warranted. This manuscript has the potential to be impactful in the Dystroglycanopathy and general neurobiology fields.

Addressed in the “Recommendation for Authors” section below

Reviewer #3 (Public Review):

The study presents a systematic analysis of how a range of dystroglycan mutations alter CCK/CB1 axonal targeting and inhibition in hippocampal CA1 and impact seizure susceptibility. The study follows up on prior literature identifying a role for dystroglycan in CCK/CB1 synapse formation. The careful assay includes comparison of 5 distinct dystroglycan mutation types known to be associated with varying degrees of muscular dystrophy phenotypes: a forebrain specific Dag1 knockout in excitatory neurons at 10.5, a forebrain specific knockout of the glycosyltransferase enzyme in excitatory neurons, mice with deletion of the intracellular domain of beta-Dag1 and 2 lines with missense mutations with milder phenotypes. They show that forebrain glutamatergic deletion of Dag1 or glycosyltransferase alters cortical lamination while lamination is preserved in mice with deletion of the intracellular domain or missense mutation.

The study extends prior works by identifying that forebrain deletion of Dag1 or glycosyltransferase in excitatory neurons impairs CCK/CB1 and not PV axonal targeting and CB1 basket formation around CA1 pyramidal cells. Mice with deletion of the intracellular domain or missense mutation show limited reductions in CCK/CB1 fibers in CA1. Carbachol enhancement of CA1 IPSCs was reduced both in forebrain knockouts. Interestingly, carbachol enhancement of CA1 IPSCs was reduced when the intracellular domain of beta-Dag1was deleted, but not I the missense mutations, suggesting a role of the intracellular domain in synapse maintenance. All lines except the missense mutations, showed increased susceptibility to chemically induced behavioral seizures. Together, the study, is carefully designed, well controlled and systematic. The results advance prior findings of the role for dystroglycans in CCK/CB1 innervations of PCs by demonstrating effects of more selective cellular deletions and site specific mutations in extracellular and intracellular domains. The interesting finding that deletion of intracellular domain reduces both CB1 terminals in CA1 and carbachol modulation of IPSCs warrants further analysis. Lack of EEG evaluation of seizure latency is a limitation.

Specific comments

• Whether CCK/CB1 cell numbers in the CA1 are differentially affected in the transgenic mice is not clarified.

This is a good point; we have now addressed this in Figure 3, Supplement 2 (new data; text lines 234-245). In brief, using two different markers (NECAB1 and NECAB2), we see no change in the number of CCK+/CB1R+ INs in the mutant mice.

• 2. Whether basal synaptic inhibition is altered by the changes in CCK innervation is not examined.

We apologize for the confusion. This is addressed in the text, lines 371-375:

“Notably, even baseline sIPSC frequency was reduced in Dag1cyto/- mutants (2.27±1.70 Hz) compared to WT controls (4.46±2.04 Hz, p = 0.002), whereas baseline sIPSC frequencies appeared normal in all other mutants when compared to their respective controls.”

Reviewer #1 (Recommendations For The Authors):

Line 321- CCH-mediated CHANGE in sIPSC amplitude...

This has been corrected (now line 356)

Reviewer #2 (Recommendations For The Authors):

Major Comments:

• Disruption of the dystroglycan (and subsequent glycosyltransferase proteins) in the brain would likely impact laminin localization and cytoskeletal stability of the dystroglycanprotein complex. The authors should assess (via immunolabeling) the disruption laminin using laminin IF in the various conditional mouse model forebrain sections.

We have stained brains from Dag1, Pomt2, and Dag1cyto mutants with an antibody to Laminin (new data; Figure 2, Supplement 2; text lines 191-205). Briefly, the data clearly shows that laminin staining is abnormal on the pial surface and in the blood vessels of the Dag1;Emx1-cre mutants. This is less severe in the Pomt2;Emx1 mutants, and normal in the Dag1cyto mutants. We also examined higher magnification of laminin staining in hippocampal SP around the pyramidal cells. Laminin in the region was diffuse (not synaptically localized) and there was no difference between any of the mutants and their respective controls (data not shown).

• 2. The biggest question(s) I have is if the synaptic defects that were measured (Fig 6) in the spontaneous inhibitory post-synaptic currents (sIPSCs) could be rescued as a function of the glycosylation of dystroglycan? While ribitol/CDP-ribose has been shown to enhance alpha-dystroglycan glycosylation and total glycosylation, it might be appropriate here. NADplus exogenous supplementation has been (Ortez-Cordero et al., eLife, 2021) has a faster acting effect on glycosylation of dystroglycan and may work in this context. Can the authors add NADplus prior to their CCK+/CB1R+ IN recordings and evaluate synaptic current effects to determine if glycosylation rescue can actually occur?

We are very much interested in the potential to rescue synaptic defects in the various mutants, and this is an active area of study for us going forward. However, we do not think the suggested experiments involving ribitol/NADplus supplementation are likely to work in our specific experiments with these models. In Dag1;Emx1-Cre and Pomt2;Emx1-Cre mice, which show the most dramatic phenotype, there is no O-mannosyl chain ini5ated for ribitol to act upon. In the Dag1Cyto mice, matriglycan is normal and therefore ribitol supplementation is unlikely to have an effect. In B4Gat1 and FKRP mutants, while matriglycan is reduced, there is no significant functional synaptic defect observed. Therefore, even if ribitol was able to increase matriglycan in these two mutants, we would be unable to detect a functional difference. As a side note, while the NADplus supplementation is an interesting idea, the previous study cited did these experiments in vitro in cell lines, so it is not clear if this would have the same effect in vivo. In addition, the time frame that they analyzed was following 24-72 hours of supplementation in cultured cells, which led to ~10% increase in IIH6 at 24 hours. We are unable to incubate acute slices for that amount of time prior to our recordings.

• 3. Minor point. Genetic abbreviation for POMT2 should be "Pomt2", unless some other justification is provided by the authors. I believe the other mutations introduced (e.g. FKRP P448L are humanized mutations).

This has been corrected throughout

• 4. While dystroglycan glycosylation using the IIHC6 antibody is important for proper localization, the core DAG-6F4 monocloncal antibody (DSHB Iowa Hybridoma Bank) would inform you if there is actual disruption in the amount of dystroglycan protein translation and/or production in the forebrain. Can the authors address this question on total dystroglycan production?

This is a great suggestion. We obtained both the DAG-6F4 monoclonal antibody from DSHB and a monoclonal antibody to alpha-Dag1 from Abcam (45-3) and tried using them for immunostaining, but they did not work with brain tissue. However, we were able to use an antibody to beta-Dag1 (Leica, B-DG-CE) for immunostaining. This new data is included in Figure 1, Supplement 2 (text lines 134-140) and shows that as expected, beta-Dag1 is completely gone in Dag1;Emx1-Cre and Dag1Cyto mutants. In the Pomt2;Emx1-Cre mutants, betaDag1 is present but no longer has the punctate appearance consistent with synaptic localization. We have added a section in the discussion expanding on the interpretation of the data, lines 449-462.

• 5. Please comment more on the structural changes in the forebrain and the presence or lack thereof cobblestone (e.g. lissencephaly) in the POMT2 mutant mice (and the other dystroglycanopathy models)? There appears to be some discordance with that and the human Walker Warburg Syndrome (WWS) patients.

The Pomt2;Emx1-cre mutants show a cobblestone phenotype (identical to the Dag1;Emx1-Cre mutants), see Figure 2. This is consistent with these two models having a complete loss of Dag1 function, and therefore modeling the most severe forms of dystroglycanopathy (WWS, MEB). In contrast, the B4Gat1 and FKRP mutants show relatively normal cortical migration because these mutants are hypomorphic and therefore retain some degree of functional Dag1. These two mice model a milder form of dystroglycanopathy. We have clarified this on lines 188-190 and 573-578.

• 6. Line 577. Minor typo, statement ended in a comma, versus a period.

Done

• 7. Methods. Please report on the sex of the mice used in the experiments.

Mice of both sexes were used throughout the study. This has been clarified in the methods section, and we have added information regarding how many mice of each sex were used in each experiment in supplemental table 1

Reviewer #3 (Recommendations For The Authors):

Additional Specific Comments,

• Although authors include n slice/animals and other details in the methodology, including data as % changes and n (slices/animals) in results will greatly improve the readability.

We have clarified that only one cell per slice was used for physiological recordings (Figure 6) in the methods section, as CCh does not wash out.

• 2. IPSCs are measured as inward currents in high chloride with AMPA blockers which is appropriate. However, Mg was appears to be low (1 mM) in cutting solution. Was this the case in the recording solution. If so, why were NMDA blockers not used.

To clarify, 10mM Mg was included in the cutting solution, and 1mM Mg was included in the recording solution. When the cell is clamped at -70mV, 1mM Mg2+ is sufficient to block NMDA receptors: haps://www.nature.com/ar5cles/309261a0

https://doi.org/10.7554/eLife.87965.3.sa4

Article and author information

Author details

  1. Jennifer N Jahncke

    Neuroscience Graduate Program, Oregon Health & Science University, Portland, United States
    Contribution
    Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2319-6109
  2. Daniel S Miller

    Neuroscience Graduate Program, Oregon Health & Science University, Portland, United States
    Contribution
    Funding acquisition, Investigation, Methodology, Writing - review and editing
    Competing interests
    No competing interests declared
  3. Milana Krush

    Neuroscience Graduate Program, Oregon Health & Science University, Portland, United States
    Contribution
    Investigation, Writing - review and editing
    Competing interests
    No competing interests declared
  4. Eric Schnell

    1. Operative Care Division, Portland VA Health Care System, Portland, United States
    2. Anesthesiology and Perioperative Medicine, Oregon Health & Science University, Portland, United States
    Contribution
    Conceptualization, Supervision, Project administration, Writing - review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5623-5015
  5. Kevin M Wright

    Vollum Institute, Oregon Health & Science University, Portland, United States
    Contribution
    Conceptualization, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing - review and editing
    For correspondence
    wrighke@ohsu.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5094-5270

Funding

National Institutes of Health (R01NS091027)

  • Kevin M Wright

National Institutes of Health (F31NS120649)

  • Jennifer N Jahncke

National Institutes of Health (F31NS108522)

  • Daniel S Miller

Cure CMD

  • Kevin M Wright

Muscular Dystrophy Association (https://doi.org/10.55762/mda.1061101.pc.gr.174090)

  • Kevin M Wright

National Institutes of Health (R01NS126247)

  • Eric Schnell

Department of Defense (W81XWH-18-1-0598)

  • Eric Schnell

Veterans Administration (I01-BX004938)

  • Eric Schnell

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

This work was funded by NIH Grants R01NS091027 (KMW), R01NS126247 (ES) CureCMD (KMW), F31NS120649 (JNJ), F31NS108522 (DSM), P30NS061800 (OHSU ALM), VA I01-BX004938 (ES), Department of Defense W81XWH-18-1-0598 (ES). The contents of this manuscript do not represent the views of the US Department of Veterans Affairs or the US government.

Ethics

This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (TR02_IP00000539) and every effort was made to minimize suffering.

Senior Editor

  1. Lu Chen, Stanford University, United States

Reviewing Editor

  1. Linda Overstreet-Wadiche, University of Alabama at Birmingham, United States

Version history

  1. Preprint posted: February 28, 2023 (view preprint)
  2. Sent for peer review: March 27, 2023
  3. Preprint posted: May 17, 2023 (view preprint)
  4. Preprint posted: November 22, 2023 (view preprint)
  5. Version of Record published: January 5, 2024 (version 1)

Cite all versions

You can cite all versions using the DOI https://doi.org/10.7554/eLife.87965. This DOI represents all versions, and will always resolve to the latest one.

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 285
    Page views
  • 42
    Downloads
  • 0
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jennifer N Jahncke
  2. Daniel S Miller
  3. Milana Krush
  4. Eric Schnell
  5. Kevin M Wright
(2024)
Inhibitory CCK+ basket synapse defects in mouse models of dystroglycanopathy
eLife 12:RP87965.
https://doi.org/10.7554/eLife.87965.3

Share this article

https://doi.org/10.7554/eLife.87965

Further reading

    1. Neuroscience
    Eyal Y Kimchi, Anthony Burgos-Robles ... Kay M Tye
    Research Article

    Basal forebrain cholinergic neurons modulate how organisms process and respond to environmental stimuli through impacts on arousal, attention, and memory. It is unknown, however, whether basal forebrain cholinergic neurons are directly involved in conditioned behavior, independent of secondary roles in the processing of external stimuli. Using fluorescent imaging, we found that cholinergic neurons are active during behavioral responding for a reward – even prior to reward delivery and in the absence of discrete stimuli. Photostimulation of basal forebrain cholinergic neurons, or their terminals in the basolateral amygdala (BLA), selectively promoted conditioned responding (licking), but not unconditioned behavior nor innate motor outputs. In vivo electrophysiological recordings during cholinergic photostimulation revealed reward-contingency-dependent suppression of BLA neural activity, but not prefrontal cortex. Finally, ex vivo experiments demonstrated that photostimulation of cholinergic terminals suppressed BLA projection neuron activity via monosynaptic muscarinic receptor signaling, while also facilitating firing in BLA GABAergic interneurons. Taken together, we show that the neural and behavioral effects of basal forebrain cholinergic activation are modulated by reward contingency in a target-specific manner.

    1. Neuroscience
    Olgerta Asko, Alejandro Omar Blenkmann ... Anne-Kristin Solbakk
    Research Article Updated

    Orbitofrontal cortex (OFC) is classically linked to inhibitory control, emotion regulation, and reward processing. Recent perspectives propose that the OFC also generates predictions about perceptual events, actions, and their outcomes. We tested the role of the OFC in detecting violations of prediction at two levels of abstraction (i.e., hierarchical predictive processing) by studying the event-related potentials (ERPs) of patients with focal OFC lesions (n = 12) and healthy controls (n = 14) while they detected deviant sequences of tones in a local–global paradigm. The structural regularities of the tones were controlled at two hierarchical levels by rules defined at a local (i.e., between tones within sequences) and at a global (i.e., between sequences) level. In OFC patients, ERPs elicited by standard tones were unaffected at both local and global levels compared to controls. However, patients showed an attenuated mismatch negativity (MMN) and P3a to local prediction violation, as well as a diminished MMN followed by a delayed P3a to the combined local and global level prediction violation. The subsequent P3b component to conditions involving violations of prediction at the level of global rules was preserved in the OFC group. Comparable effects were absent in patients with lesions restricted to the lateral PFC, which lends a degree of anatomical specificity to the altered predictive processing resulting from OFC lesion. Overall, the altered magnitudes and time courses of MMN/P3a responses after lesions to the OFC indicate that the neural correlates of detection of auditory regularity violation are impacted at two hierarchical levels of rule abstraction.